



**PYC**  
Therapeutics

## **PYC THERAPEUTICS LIMITED**

ACN 098 391 961

## **RETAIL OFFER BOOKLET**

1 for 4 accelerated non-renounceable pro-rata entitlement offer of fully paid ordinary shares at \$0.08 per New Share

**Retail Entitlement Offer closes at 5.00pm AWST Monday, 8 April 2024 (unless varied)**

If you are an Eligible Retail Shareholder, this Retail Offer Booklet together with the personalised Entitlement and Acceptance Form which accompanies it are important documents that require your immediate attention. These documents should be read in their entirety.

This Retail Offer Booklet is not a prospectus under the *Corporations Act 2001* (Cth) (**Corporations Act**) and has not been lodged with the Australian Securities and Investments Commission (**ASIC**). You should consult your stockbroker, solicitor, accountant or other professional adviser if you have any questions about the Retail Entitlement Offer.

**THIS RETAIL OFFER BOOKLET MAY NOT BE RELEASED TO USA WIRE SERVICES OR DISTRIBUTED IN THE UNITED STATES OF AMERICA**

## **IMPORTANT NOTICES**

This Retail Offer Booklet has been prepared by PYC Therapeutics Limited ACN 098 391 961 (**PYC** or the **Company**) and is dated 20 March 2024. Capitalised terms in this Section have the meaning given to them in this Retail Offer Booklet.

This Retail Entitlement Offer is made in accordance with section 708AA of the Corporations Act (as modified by *ASIC Corporations (Non-Traditional Rights Issues) Instrument 2016/84*).

This Retail Offer Booklet does not contain all of the information which an investor may require to make an informed investment decision. The information in this Retail Offer Booklet does not constitute financial product advice and does not take into account your investment objectives, financial situation or particular needs.

This Retail Offer Booklet should be read in its entirety before you decide to participate in the Retail Entitlement Offer. This Retail Offer Booklet is not a prospectus or other disclosure document under the Corporations Act and has not been lodged with ASIC.

By paying for your New Shares through BPay® or EFT in accordance with the instructions on the Entitlement and Acceptance Form, you acknowledge that you have read this Retail Offer Booklet and you have acted in accordance with and agree to the terms of the Retail Entitlement Offer detailed in this Retail Offer Booklet.

### **International offer restrictions**

This Retail Offer Booklet and the accompanying Entitlement and Acceptance Form do not constitute an offer or invitation in any place in which, or to any person to whom, it would not be lawful to make such an offer or invitation. In particular, this Retail Offer Booklet does not constitute an offer to Ineligible Retail Shareholders and may not be distributed in the United States and the New Shares may not be offered or sold,

directly or indirectly, to persons in the United States.

This Retail Offer Booklet is not to be distributed in, and no offer of New Shares is to be made, in countries other than Australia and New Zealand. No action has been taken to register or qualify the Retail Entitlement Offer or the New Shares, or otherwise permit the public offering of the New Shares, in any jurisdiction other than Australia and New Zealand.

The distribution of this Retail Offer Booklet (including an electronic copy) outside Australia and New Zealand, is restricted by law. If you come into possession of the information in this Retail Offer Booklet, you should observe such restrictions, including those set out in this Retail Offer Booklet. Any non-compliance with these restrictions could contravene applicable securities laws.

### **New Zealand**

The New Shares are not being offered or sold to the public within New Zealand other than to existing shareholders of PYC with registered addresses in New Zealand to whom the offer of New Shares is being made in reliance on the Financial Markets Conduct Act 2013 (New Zealand) and the Financial Markets Conduct (Incidental Offers) Exemption Notice 2021 (New Zealand).

This document has been prepared in compliance with Australian law and has not been registered, filed with or approved by any New Zealand regulatory authority under the Financial Markets Conduct Act 2013 (New Zealand). This document is not an investment statement or prospectus under New Zealand law and is not required to, and may not, contain all the information that an investment statement or prospectus under New Zealand law is required to contain.

### **No offer in the United States**

None of the information in this Retail Offer Booklet or the Entitlement and Acceptance Form constitutes an offer to sell, or the

solicitation of an offer to buy, any securities in the United States. This Retail Offer Booklet may not be released to US wire services or distributed, directly or indirectly, to any person in the United States.

The New Shares have not been, and will not be, registered under the U.S. Securities Act or the securities laws of any state or other jurisdiction of the United States. The Entitlements may not be taken up by persons in the United States or by persons (including nominees or custodians) who are acting for the account or benefit of a person in the United States, and the New Shares may not be offered, sold or resold in the United States or to, or for the account or benefit of, a person in the United States except in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act and applicable securities laws of any state or other jurisdiction in the United States. The New Shares in the Retail Entitlement Offer may only be offered and sold outside the United States in "offshore transactions" in reliance on Regulation S under the U.S. Securities Act.

### **Definitions and time**

Defined terms used in this Retail Offer Booklet are set out in the glossary of terms in Section 7. All references to time are to the time in Perth, Western Australia unless otherwise indicated.

### **Foreign exchange**

All references to "\$" are AUD unless otherwise noted.

### **No representations**

No person is authorised to give any information or to make any representation in connection with the Retail Entitlement Offer which is not contained in this Retail Offer Booklet. Any information or representation in connection with the Retail Entitlement Offer not contained in the Retail Offer Booklet

may not be relied upon as having been authorised by PYC or any of its officers.

### **Past performance**

Investors should note that PYC's past performance, including past share price performance, cannot be relied upon as an indicator of (and provides no guidance as to) PYC's future performance including PYC's future financial position or share price performance.

### **Future performance**

This Retail Offer Booklet contains certain forward-looking statements, including statements with respect to the financial condition, results of operations, projects and business of PYC, certain plans and objectives of the management of PYC. These statements relate to expectations, beliefs, intentions or strategies regarding the future. Forward looking statements may be identified by the use of words like 'anticipate', 'believe', 'aim', 'estimate', 'expect', 'intend', 'may', 'plan', 'project', 'will', 'should', 'seek' and similar expressions. These forward-looking statements reflect views and assumptions with respect to future events as of the date of this Retail Offer Booklet. However, they are not guarantees of future performance. They involve known and unknown risks, uncertainties and other factors which are subject to change without notice, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct.

Forward-looking statements are provided as a general guide only and there can be no assurance that actual outcomes will not differ materially from these statements. Neither PYC, nor any other person, gives any representation, warranty, assurance or guarantee, express or implied, as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this Retail Offer Booklet, or that the occurrence of the events

expressed or implied in any forward-looking statement will actually occur. In particular, such forward-looking statements are subject to significant uncertainties and contingencies, many of which are outside the control of PYC and its directors and management. A number of important factors could cause actual results or performance to differ materially from the forward looking statements. Applicants should consider the forward looking statements contained in this Retail Offer Booklet in light of those disclosures. Except as required by law or regulation (including ASX Listing Rules), PYC undertakes no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise.

### **Risks**

Refer to the 'Key risks' section of the Investor Presentation included in Section 6 of this Retail Offer Booklet for summary of general and specific risk factors that may affect PYC.

### **Trading New Shares**

PYC will have no responsibility and disclaims all liability (to the maximum extent permitted by law) to persons who trade New Shares they believe will be issued to them before they receive their holding statements, whether on the basis of confirmation of the allocation provided by PYC or the Share Registry or otherwise, or who otherwise trade or purport to trade New Shares in error or which they do not hold or are not entitled to.

If you are in any doubt as to these matters you should first consult with your stockbroker, solicitor, accountant or other professional advisor.

### **Rounding**

Any discrepancies between totals and sums and components in tables and figures contained in this Retail Offer Booklet are due to rounding.

### **Other Important Information**

Please read this Retail Offer Booklet in full including the other important information set out in Section 6.

## LETTER FROM THE CHIEF EXECUTIVE OFFICER

Dear Eligible Retail Shareholder

### **PYC Therapeutics Limited – Accelerated Non-Renounceable Entitlement Offer**

On behalf of PYC Therapeutics Limited (**PYC** or **Company**), I am pleased to present you with an opportunity to participate in the retail component of a pro-rata accelerated non-renounceable entitlement offer to eligible shareholders on the basis of one (1) new share for every four (4) existing shares held which is intended to raise approximately A\$74.6 million (before costs) (**Entitlement Offer**).

The Entitlement Offer will comprise the issue of up to approximately 933 million new fully paid ordinary shares in PYC (**New Shares**) at an offer price of \$0.080 (**Offer Price**) per New Share, which represents a:

- 5.9% discount to the last traded price of A\$0.085 on 13 March 2024;
- 4.8% discount to the Theoretical Ex-Rights Price (**TERP**)<sup>1</sup> of A\$0.084 per share; and
- 1.1% discount to the 5-day volume weighted average price of shares up to and including 13 March 2024.

### **Use of proceeds**

The proceeds from the Entitlement Offer will be used to:

- progress PYC's first blinding eye disease drug candidate into mid and late-stage human trials
- progress PYC's second blinding eye disease drug candidate into early and mid-stage human trials
- progress PYC's polycystic kidney disease drug candidate into human trials

---

<sup>1</sup> The theoretical ex-rights price is theoretical price at which PYC shares should trade immediately after the ex-date for the Entitlement Offer. The TERP is a theoretical calculation only and the actual price at which PYC's shares trade immediately after the ex-date for the Entitlement Offer will depend on many factors and may not equal the TERP. TERP is calculated by reference to PYC's closing price of A\$0.085 on 13 March 2024.

- support progression of the Company's Phelan-McDermid Syndrome drug program and drug discovery activities
- general working capital and Entitlement Offer costs

As mentioned, the Equity Raising is not underwritten. If the proceeds from the Equity Raising are less than is required to meet the Company's proposed use of funds, the Company may review its proposed use of funds (including whether to scale back or defer investments) as well as consider alternative funding options.

### **Entitlement Offer**

The Entitlement Offer comprises an accelerated institutional component (**Institutional Entitlement Offer**), and a retail component (**Retail Entitlement Offer**).

This document (**Retail Offer Booklet**) relates to the Retail Entitlement Offer only.

The Entitlement Offer is not underwritten.

### **Institutional Entitlement Offer**

As announced by PYC on 18 March 2024, the Institutional Entitlement Offer was successfully completed having received firm commitments to raise approximately \$40 million (before costs). For more information, please see the Company's ASX announcement dated 18 March 2024 included in the Annexure

### **Retail Entitlement Offer**

Under the Retail Entitlement Offer, Eligible Retail Shareholders are entitled to subscribe for 1 New Share for every 4 Shares held on the Record Date at an Offer Price of \$0.08 per New Share. This is the same price that was offered to Eligible Institutional Investors who participated in the Institutional Entitlement Offer.

The Retail Entitlement Offer is intended to raise up to a further approximately \$34.6 million (before costs).

The number of New Shares to which you are entitled to subscribe for is detailed in the Entitlement and Acceptance Form that accompanies this Retail Offer Booklet.

The Entitlement Offer is non-renounceable and therefore your Entitlements will not be tradeable on the ASX or otherwise transferrable. If you do not participate in the Retail Entitlement Offer, your Entitlement will lapse and you will receive no value for those lapsed Entitlements.

The Directors reserve the right to place any Shortfall Shares at their discretion within 3 months after the Retail Closing Date, subject to the requirements of the ASX Listing Rules and the Corporations Act.

## Other information

This Retail Offer Booklet contains important information, including:

- (a) information on the Entitlement Offer and key risks for you to consider;
- (b) instructions on how to apply, detailing how to participate in the Retail Entitlement Offer if you choose to do so, and a timetable of key dates;
- (c) a personalised Entitlement and Acceptance Form which details your Entitlement, to be completed in accordance with the instructions on that form; and
- (d) instructions on how to take up all or part of your Entitlement.

**The Retail Entitlement Offer is scheduled to close at 5.00pm Perth time on Monday, 8 April 2024.**

If you decide to take this opportunity to increase your investment in the Company, you must pay your Application Monies via BPAY® or EFT, before **5.00pm Perth time on Monday, 8 April 2024**. Instructions on how to apply are set out in this Retail Offer Booklet and your Entitlement and Acceptance Form.

If you do not wish to take up any of your Entitlement, you do not have to take any action.

If you are uncertain about taking up your Entitlement you should consult your stockbroker, solicitor, accountant or other professional adviser to evaluate whether or not to participate in the Retail Entitlement Offer.

On behalf of the Board, I invite you to consider this investment opportunity and thank you for your continuing support.

Yours sincerely



**Dr Rohan Hockings**  
**Chief Executive Officer**

## **Contents**

<b>1</b>	<b>Entitlement Offer.....</b>	<b>9</b>
<b>2</b>	<b>Key dates for the Retail Entitlement Offer .....</b>	<b>10</b>
<b>3</b>	<b>Summary of options available to you .....</b>	<b>11</b>
<b>4</b>	<b>Overview of the Entitlement Offer .....</b>	<b>12</b>
<b>5</b>	<b>How to apply .....</b>	<b>14</b>
<b>6</b>	<b>Additional Information.....</b>	<b>21</b>
<b>7</b>	<b>Glossary .....</b>	<b>29</b>
	<b>Annexure ASX Announcements .....</b>	<b>34</b>

# 1 Entitlement Offer

## 1.1 Overview

Key details	
<b>Offer Price</b>	A\$0.08 per New Share
<b>Ratio</b>	1 New Share for every 4 Shares held by Eligible Retail Shareholders as at the Record Date
<b>Maximum number of New Shares to be issued under the Entitlement Offer</b>	933,216,784
<b>Maximum amount to be raised under the Entitlement Offer</b>	Up to approximately \$74.6 million
<b>Number of Shares on issue following the Entitlement Offer<sup>1,2</sup></b>	4,666,083,919
<b>Oversubscription</b>	Not accepted.
<b>Underwriting</b>	Not underwritten.

<sup>1</sup>Excludes any New Shares which may be issued under any exercise of Options. <sup>2</sup>Including the Shortfall Shares.

## 1.2 Indicative use of funds

Uses	\$ million
VP-001 clinical studies	\$21
PYC-001 completion of IND-enabling studies and commencement of clinical trials	\$22
PYC-003 completion of pre-clinical and IND-enabling studies and commencement of clinical trials	\$35
PYC-002 completion of pre-clinical and IND-enabling studies	\$18
R&D and lab expenses	\$12
General and corporate expenses	\$4
Offer costs and working capital	\$2
<b>Total</b>	<b>\$114</b>

Further detail of the proposed sources and uses of funds is set out in the Investor Presentation included in the Annexure (and, in particular, from slide 14 in that presentation).

## 2 Key dates for the Retail Entitlement Offer

Event	Timing
Announcement of Entitlement Offer	Thursday, 14 March 2024
Record Date for Entitlement Offer	4.00pm on Monday, 18 March 2024
Settlement of New Shares under Institutional Entitlement Offer	Monday, 25 March 2024
Issue of New Shares under the Institutional Entitlement Offer	Tuesday, 26 March 2024
Retail Entitlement Offer opens	Wednesday, 20 March 2024
Retail Entitlement Offer closes (Retail Closing Date)	Monday, 8 April 2024
Issue of New Shares under Retail Entitlement Offer	Monday, 15 April 2024
New Shares issued under Retail Entitlement Offer commence trading on ASX	Tuesday, 16 April 2024
Despatch to Shareholders of holding statements under the Retail Entitlement Offer	Wednesday, 17 April 2024

This timetable (**Indicative Timetable**) is indicative only and subject to change without notice. Times are Perth times.

The commencement of quotation of New Shares is subject to confirmation from ASX. Subject to the requirements of the Corporations Act, ASX Listing Rules and any other applicable laws, PYC reserves the right to amend this timetable at any time, including extending the Retail Entitlement Offer Period or accepting late applications, either generally or in particular cases, and to withdraw the Retail Entitlement Offer, without notice. Any extension of the Retail Closing Date will have a consequential effect on the issue date of New Shares.

PYC also reserves the right not to proceed with the Retail Entitlement Offer in whole or in part at any time prior to allotment and issue of the New Shares. In that event, the relevant Application Monies will be returned in full to Applicants (without interest).

### Enquiries

If you have any questions, please call the Automatic Share Registry on 1300 288 664 (within Australia) or +61 2 9698 5414 (International) from 8.30am to 5.00pm (Sydney time) Monday to Friday during the Retail Offer Period. Alternatively, you can access information about the Retail Entitlement Offer online at [www.asx.com.au](http://www.asx.com.au) or [www.pyctx.com](http://www.pyctx.com).

### 3 Summary of options available to you

If you are an Eligible Retail Shareholder, you may take one of the following actions:

- (a) take up all of your Entitlement;
- (b) take up part of your Entitlement and allow the balance to lapse, in which case you will receive no value for the lapsed balance; or
- (c) do nothing, in which case your full Entitlement will lapse and you will receive no value for your lapsed Entitlement.

If you are a retail shareholder who is not an Eligible Retail Shareholder, you are an “**Ineligible Retail Shareholder**”. Ineligible Retail Shareholders are not entitled to participate in the Entitlement Offer.

Options available to you	Key considerations
<p><b>Option 1:</b> <i>Take up all of your Entitlement</i></p>	<p>You may elect to purchase your full Entitlement of New Shares at the Offer Price (see Section 5 (<i>How to apply</i>) for instructions on how to take up your Entitlement).</p> <p>You may not apply for New Shares in excess of your Entitlement.</p>
<p><b>Option 2:</b> <i>Take up part of your Entitlement</i></p>	<p>If you only take up part of your Entitlement, the part not taken up will lapse. See Section 5 (<i>How to apply</i>) for instructions on how to take up part of your Entitlement.</p> <p>Your Entitlement is non-renounceable, which means it is non-transferrable and cannot be sold, traded on ASX or any other exchange, nor can it be privately transferred.</p> <p>If you do not take up your Entitlement in full you will not receive any payment or value for the part not taken up. In addition, you will have your percentage holding in PYC reduced as a result of dilution by the shares issued under the Entitlement Offer.</p>
<p><b>Option 2:</b> <i>Do nothing, in which case your full Entitlement will lapse</i></p>	<p>If you do not take up your Entitlement, you will not be allocated New Shares and your Entitlement will lapse. You will not receive any payment or value for your lapsed Entitlement and your percentage holding in PYC will be reduced.</p>

**If you have any doubt about how you should deal with your Entitlements, you should seek professional advice from an adviser who is licensed by ASIC to give that advice before making any investment decision.**

## 4 Overview of the Entitlement Offer

### 4.1 Overview

The Entitlement Offer is the opportunity for Eligible Shareholders to purchase 1 New Share for every 4 Existing Shares held as at the Record Date of 4.00pm Perth time on Monday, 18 March 2024, at the Offer Price of \$0.08 per New Share to raise up to approximately \$74.6 million (before costs).

The Company intends to use the proceeds of the Entitlement Offer in accordance with the use of funds outlined in Section 1.2 and as shown in the Investor Presentation included in the Annexure.

The Entitlement Offer has two components:

- **Institutional Entitlement Offer** – an accelerated institutional component open to Eligible Institutional Shareholders; and
- **Retail Entitlement Offer** – a retail component open to Eligible Retail Shareholders in Australia or New Zealand.

This Retail Offer Booklet relates to the Retail Entitlement Offer.

The offer ratio and Offer Price for New Shares under the Retail Entitlement Offer are the same as for the Institutional Entitlement Offer.

Please refer to the Investor Presentation accompanying the Retail Offer Booklet for further information regarding the purpose of the Entitlement Offer and proposed use of funds, as well as the key risks associated with an investment in PYC. You should also consider the ASX announcements and other publicly available information about PYC at [www.asx.com.au](http://www.asx.com.au) and [www.pyctx.com](http://www.pyctx.com).

### 4.2 Institutional Entitlement Offer

The Institutional Entitlement Offer was conducted between 14 March 2024 and 15 March 2024, and settlement of the Institutional Entitlement Offer is expected to occur on Monday, 25 March 2024.

The Institutional Entitlement Offer was fully subscribed, having received firm commitments to take up approximately 500,000,000 New Shares to raise a total of \$40 million (before costs). New Shares subscribed for under the Institutional Entitlement Offer are expected to settle on Monday 25 March 2024.

Please see the Company's ASX announcement dated 18 March 2024 (included in the Annexure) for further information about the outcome of the Institutional Entitlement Offer.

#### 4.3 **Retail Entitlement Offer**

Eligible Retail Shareholders are being invited to apply for all or part of their Entitlement and are being sent this Retail Offer Booklet with a personalised Entitlement and Acceptance Form. You should note that not all Shareholders will be eligible to participate in the Retail Entitlement Offer. Please read Section 6 for further information.

The Retail Entitlement Offer seeks to raise up to approximately \$34.6 million (before costs). The offer ratio and Offer Price under the Retail Entitlement Offer are the same as the Institutional Entitlement Offer.

The Retail Entitlement Offer opens on **20 March 2024** and will close at **5.00pm (Perth time)** on **8 April 2024** (unless extended).

#### 4.4 **Underwriting**

The Entitlement Offer is not underwritten.

#### 4.5 **Oversubscription**

No oversubscription under the Entitlement Offer will be accepted by the Company.

#### 4.6 **Shortfall**

A shortfall may arise if the aggregate of the total valid Applications received for New Shares under the Entitlement Offer is less than the total number of New Shares offered under the Entitlement Offer (**Shortfall**).

The Directors reserve the right, subject to the requirements of the Corporations Act and Listing Rules, to place any New Shares under the Shortfall (**Shortfall Shares**) at their discretion within 3 months after the Retail Closing Date. In exercising this discretion, the Board will take into consideration a number of factors, including ensuring the Company has an appropriate and optimal Shareholder base, which may be achieved through the introduction of new Institutional Investors.

No person will be permitted by the Company to subscribe for and be issued Shortfall Shares if doing so will cause the person (or any associate of that person) to be in breach of the law (including section 606 of the Corporations Act) or the ASX Listing Rules.

Any Shortfall Shares will be issued at a price not less than the Offer Price under the Retail Entitlement Offer. The Directors reserve the right to issue any New Shares at a price higher than the Offer Price.

#### 4.7 **Brokerage**

No brokerage fee is payable by Eligible Shareholders who accept their Entitlement.

#### 4.8 **Withdrawal of the Entitlement Offer**

Subject to applicable law, PYC reserves the right to withdraw the Entitlement Offer at any time before the issue of New Shares, in which case PYC will refund any Application Monies already received in accordance with the Corporations Act and will do so without interest being payable to Applicants.

To the fullest extent permitted by law, you agree that any Application Monies paid by you to PYC will not entitle you to receive any interest and that any interest earned in respect of Application Monies will belong to PYC.

#### 4.9 **Minimum subscription**

There is no minimum subscription. The Entitlement Offer is not underwritten.

#### 4.10 **New Share terms**

Upon issue, New Shares will rank equally with all Existing Shares.

### **5 How to apply**

#### 5.1 **Your Entitlement**

Your Entitlement is detailed on your personalised entitlement and acceptance form (**Entitlement and Acceptance Form**) and has been calculated as one (1) New Share for every four (4) Shares held by you as at the Record Date. If the result is not a whole number, your Entitlement will be rounded up to the nearest whole number of New Shares.

If you have more than one registered holding of Shares, you will have more than one personalised Entitlement and Acceptance Form and you will have separate Entitlements for each separate holding. Nominees and custodians, please see Section 5.11 below.

New Shares issued pursuant to the Retail Entitlement Offer will be fully paid and rank equally with existing Shares on issue.

The Entitlement stated on your personalised Entitlement and Acceptance Form may be in excess of the actual Entitlement you may be permitted to take up (see definition of Eligible Retail Shareholder in Section 6.1).

#### 5.2 **Consider your personal investment objectives and circumstances**

The Retail Entitlement Offer is being made pursuant to provisions of the Corporations Act (as modified by *ASIC Corporations (Non-Traditional Rights Issues) Instrument 2016/84*) which allows entitlement offers to be made without a prospectus.

This Retail Offer Booklet does not detail all of the information which may be required in order to make an informed decision regarding an application for New Shares offered under the Retail Entitlement Offer. As a result, it is important for you to carefully read and understand the information on PYC and the Retail Entitlement Offer made publicly available and other PYC ASX announcements, prior to accepting all or part of your Entitlement or doing nothing in respect of your Entitlement. In particular, please refer to this Retail Offer Booklet, PYC's half year and annual reports, Appendices 4D and 4E and other announcements lodged with ASX (including announcements which may be made by PYC after publication of this Retail Offer Booklet).

Please consult with your stockbroker, accountant or other independent professional adviser if you have any queries or are uncertain about any aspect of the Retail Entitlement Offer. You should also refer to the "Key Risks" section in Appendix A of the Investor Presentation released to ASX which is included in the Annexure.

#### 5.3 **Options available to you**

If you are an Eligible Retail Shareholder, you may do any one of the following:

- (a) take up all of your Entitlement (refer to Section 5.4);
- (b) take up some but not all of your Entitlement (refer to Section 5.5); or
- (c) do nothing, in which case all of your Entitlement will lapse and you will receive no value for those lapsed Entitlements (refer to Section 5.6).

Ineligible Retail Shareholders may not participate in the Retail Entitlement Offer.

PYC reserves the right to reject any Application that is received after the Retail Closing Date.

You may not apply for New Shares in excess of your Entitlement. The Directors reserve the right to issue any Shortfall under the Entitlement Offer at their discretion. For further information, please see Section 4.5.

PYC also reserves the right (in its absolute discretion) to reduce the number of New Shares issued to Eligible Retail Shareholders, or persons claiming to be Eligible Retail Shareholders, if PYC believes their claims to be overstated or if they or their nominees fail to provide information to substantiate their claims to PYC's satisfaction.

**The Retail Closing Date for acceptance of the Retail Entitlement Offer is 5.00pm (Perth time) on 8 April 2024 (unless extended).**

Further details regarding your options are provided below.

#### 5.4 **Taking up all of your Entitlement**

If you wish to take up all or part of your Entitlement, payment must be made by following the instructions set out on the personalised Entitlement and Acceptance Form.

**Payment must be received by no later than 5.00pm Perth time on the Retail Closing Date.**

Eligible Retail Shareholders who participate in the Retail Entitlement Offer will see their percentage holding in PYC stay the same if they take up all of their Entitlement.

You cannot apply to take up any additional New Shares in excess of your Entitlement. Application Monies received by PYC in excess of the amount in respect of your Entitlement (**Excess Amount**) will be refunded as set out below.

If your Application Monies include an Excess Amount for additional New Shares which exceed your Entitlement, you will be refunded (without interest) the amount of the overpayment after the Retail Closing Date. Refund amounts of less than \$2.00 will be disregarded.

Refund amounts, if any, will be paid in Australian dollars by cheque sent by ordinary post to your address as recorded on the share register or by direct credit to the nominated bank account as noted on the share register. No interest will be paid on refunded amounts.

Refer to Section 5.7 for the available payment options.

#### 5.5 **Taking up part of your Entitlement and allowing the balance to lapse**

If you wish to take up part of your Entitlement, payment for the number of New Shares you wish to be allocated must be made by following the instructions set out on the personalised Entitlement and Acceptance Form.

If PYC receives an amount that is less than the Offer Price multiplied by your Entitlement, your payment will be treated as an Application for as many New Shares as your Application Monies will pay for in full. Alternatively your Application may not be accepted and as such your Application Monies will be refunded. Refund amounts of less than \$2.00 will be disregarded.

If you do not take up your Entitlement in full, any part of your Entitlement which you do not take up will lapse and you will not receive any New Shares under the Retail Entitlement Offer in respect of that part of your Entitlement.

Refer to Section 5.7 for the available payment options.

## 5.6 Entitlement not taken up

If you do not wish to accept any of your Entitlement under the Retail Entitlement Offer, you do not need to do anything.

Your Entitlement to participate in the Retail Entitlement Offer is non-renounceable, which means it is non-transferrable and cannot be sold, traded on ASX or any other exchange, nor can the Entitlement be privately transferred.

You will not receive any value for the Entitlements you choose not to take up and they will lapse worthless.

By allowing part or all of your Entitlement to lapse, you will forgo any exposure to increases or decreases in the value of the New Shares had you taken up your Entitlement in full and you will not receive any value for any part of your Entitlement which lapses. Your interest in PYC will also be diluted.

## 5.7 Payment

The method of acceptance of the Retail Entitlement Offer will depend on your method of payment being:

- (a) by BPAY® (all Eligible Retail Shareholders); or
- (b) by EFT (for Eligible Retail Shareholders registered in New Zealand who do not have an Australian bank account and are unable to submit payment via BPAY®).

Cash payments will not be accepted. Receipts for payment will not be issued.

Any Application Monies received for more than your final allocation of New Shares will be refunded as soon as practicable after the Retail Closing Date. No interest will be paid to applicants on any application monies received or refunded.

### (c) Payment by BPAY®

For payment by BPAY®, please follow the instructions on the personalised Entitlement and Acceptance Form. You can only make payment via BPAY® if you are the holder of an account with an Australian financial institution that supports BPAY® transactions.

When paying by BPAY®, please make sure you use the specific Biller Code and your unique CRN on your personalised Entitlement and Acceptance Form. If you have multiple holdings and consequently receive more than one personalised Entitlement and Acceptance Form, when taking up your Entitlement in respect of one of those holdings only use the CRN specific to that holding. If you do not use the correct CRN specific to that holding your Application will not be recognised as valid.

Please note that should you choose to pay by BPAY®:

- (i) you do not need to submit the personalised Entitlement and Acceptance Form but are taken to have made the declarations, representations and warranties on that personalised Entitlement and Acceptance Form and in this Section 5 and Section 6;
- (ii) if you do not pay for your full Entitlement, you are deemed to have taken up your Entitlement in respect of such whole number of New Shares which is covered in full by your application monies; and

- (iii) if you pay more than is required to subscribe for your Entitlement, you will be taken to have applied for your Entitlement only and the excess amount will be treated as an over payment and will be refunded after the Retail Closing Date as described above.

It is your responsibility to ensure that your BPAY® payment is received by the Share Registry by no later than the Retail Closing Date. You should be aware that your financial institution may implement earlier cut-off times with regard to electronic payment and you should therefore take this into consideration when making payment.

**(d) Payment by EFT (New Zealand only)**

For payment by EFT, please follow the instructions on the personalised Entitlement and Acceptance Form.

When paying by EFT, please make sure you use the specific account details and your Unique Reference Number on your personalised Entitlement and Acceptance Form. If you have multiple holdings and consequently receive more than one personalised Entitlement and Acceptance Form, when taking up your Entitlement in respect of one of those holdings only use the Unique Reference Number specific to that holding. If you do not use the correct Unique Reference Number specific to that holding your Application will not be recognised as valid.

Please note that should you choose to pay by EFT:

- (i) you do not need to submit the personalised Entitlement and Acceptance Form but are taken to have made the declarations, representations and warranties on that personalised Entitlement and Acceptance Form and in this Section 5 and Section 6;
- (ii) if you do not pay for your full Entitlement, you are deemed to have taken up your Entitlement in respect of such whole number of New Shares which is covered in full by your Application Monies; and
- (iii) if you pay more than is required to subscribe for your Entitlement, you will be taken to have applied for your Entitlement only and the Excess Amount will be treated as an over payment and will be refunded after the Retail Closing Date as described above.

It is your responsibility to ensure that your EFT payment is received by the Share Registry by no later than the Retail Closing Date. You should be aware that your financial institution may implement earlier cut-off times with regard to electronic payment, and, therefore, you should take this into consideration in the timing of when you make payment.

**5.8 Application Monies**

Application Monies will be held on trust for Applicants until allotment of the New Shares. Interest earned on Application Monies will be for the benefit of the Company. No interest will be paid on any Application Monies received or refunded.

**5.9 Entitlement and Acceptance Form is binding**

Completing and returning your personalised Entitlement and Acceptance Form or paying any Application Monies by EFT or BPAY® will be taken to constitute a binding acceptance of New Shares on the terms and conditions set out in this Retail Offer Booklet and, once lodged or paid, cannot be withdrawn.

If the Entitlement and Acceptance Form is not completed correctly, it may still be treated as a valid application for New Shares. The Directors' decision whether to treat an acceptance as valid and how to construe, amend or complete the Entitlement and Acceptance Form is final.

#### 5.10 Representations by acceptance

By making a payment by BPAY® or EFT, you will be deemed to have represented to PYC that you are an Eligible Retail Shareholder and:

- (a) acknowledge that you have read and understand this Retail Offer Booklet and your personalised Entitlement and Acceptance Form in their entirety;
- (b) agree to be bound by the terms of the Retail Entitlement Offer, the provisions of this Retail Offer Booklet and PYC's Constitution;
- (c) authorise PYC to register you as the holder(s) of New Shares allotted to you;
- (d) declare that all details and statements in the personalised Entitlement and Acceptance Form are complete and accurate;
- (e) declare you are over 18 years of age and have full legal capacity and power to perform all of your rights and obligations under the personalised Entitlement and Acceptance Form;
- (f) acknowledge that once PYC receives your personalised Entitlement and Acceptance Form or any payment of application monies via BPAY® or EFT, you may not withdraw your application or funds provided except as allowed by law;
- (g) agree to apply for and be issued up to the number of New Shares specified in the personalised Entitlement and Acceptance Form, or for which you have submitted payment of any application monies via BPAY® or EFT, at the Offer Price;
- (h) authorise PYC, the Share Registry and their respective officers or agents to do anything on your behalf necessary for New Shares to be issued to you, including to act on instructions of the Share Registry upon using the contact details detailed in your personalised Entitlement and Acceptance Form;
- (i) acknowledge and agree that:
  - (i) determination of eligibility of investors for the purposes of the institutional or retail components of the Entitlement Offer is determined by reference to a number of matters, including legal and regulatory requirements, logistical and registry constraints and the discretion of PYC;
  - (ii) PYC and each of its respective advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents disclaim any duty or liability (including for negligence) in respect of that determination and the exercise or otherwise of that discretion, to the maximum extent permitted by law;
- (j) represent and warrant (for the benefit of PYC and its related bodies corporate and affiliates) that you did not receive an invitation to participate in the Institutional Entitlement Offer either directly or through a nominee, are not an Ineligible Institutional Shareholder under the Institutional Entitlement Offer, are not an Ineligible Retail Shareholder (as defined in Section 6.1) and are otherwise eligible to participate in the Retail Entitlement Offer;
- (k) declare that you were the registered holder(s) at the Record Date of the Shares indicated on the personalised Entitlement and Acceptance Form as being held by you on the Record Date;

- (l) acknowledge that the information detailed in this Retail Offer Booklet and your personalised Entitlement and Acceptance Form is not investment advice nor a recommendation that New Shares are suitable for you given your investment objectives, financial situation or particular needs;
- (m) acknowledge that this Retail Offer Booklet is not a prospectus, does not detail all of the information that you may require in order to assess an investment in PYC and is given in the context of PYC's past and ongoing continuous disclosure announcements to ASX;
- (n) acknowledge the statement of risks in the "Key Risks" section of the Investor Presentation included in the Annexure of this Retail Offer Booklet, and that investments in PYC are subject to risk;
- (o) acknowledge that none of PYC or their respective related bodies corporate and affiliates and their respective directors, officers, partners, employees, representatives, agents, consultants or advisers, guarantees the performance of PYC, nor do they guarantee the repayment of capital;
- (p) agree to provide (and direct your nominee or custodian to provide) any requested substantiation of your eligibility to participate in the Retail Entitlement Offer and of your holding of Shares on the Record Date;
- (q) authorise PYC to correct any errors in your personalised Entitlement and Acceptance Form or other form provided by you;
- (r) represent and warrant that the law of any place does not prohibit you from being given this Retail Offer Booklet and the personalised Entitlement and Acceptance Form, nor does it prohibit you from making an application for New Shares and that you are otherwise eligible to participate in the Retail Entitlement Offer; and
- (s) you will also be deemed to have acknowledged, represented and warranted personally, and on behalf of each person on whose account you are acting (if any), that:
  - (i) you and each person on whose account you are acting are not in the United States;
  - (ii) you and each person on whose account you are acting understand and acknowledge that the New Shares have not been, and will not be, registered under the US Securities Act or the securities laws of any state or other jurisdiction in the United States and accordingly that the New Shares may not be offered, sold or otherwise transferred to, persons in the United States or to persons who are acting for the account or benefit of a person in the United States except in accordance with an available exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act and any other applicable securities laws;
  - (iii) you are subscribing for or purchasing New Shares outside the United States in an "offshore transaction" (as defined in Rule 902(h) under the US Securities Act) in compliance with Regulation S under the US Securities Act;
  - (iv) you have not and will not send this Retail Offer Booklet, the Entitlement and Acceptance Form or any other materials relating to the Retail Entitlement Offer to any person in the United States or any person acting for the account or benefit of a person in the United States or any other country outside Australia and New Zealand (unless you are a nominee or custodian, as provided below);

- (v) if in the future you decide to sell or otherwise transfer the New Shares, you will only do so in transactions exempt from, or not subject to, the registration requirements of the US Securities Act; but notwithstanding the foregoing, after the quotation of the New Shares commences, you may sell such New Shares in the regular way transactions on the ASX or otherwise are conducted where neither you nor any person acting on your behalf know, or has reason to know, that the sale has been pre-arranged with, or that the purchaser is, a person in the United States or a person acting for the account or benefit of a person in the United States; and
- (vi) if you are acting as a nominee or custodian, each beneficial holder on whose behalf you are paying application monies in accordance with your personalised Entitlement and Acceptance Form is resident in Australia or New Zealand or is an Institutional Investor permitted in Section 6.15 and you have not sent this Retail Offer Booklet, the Entitlement and Acceptance Form or any information relating to the Retail Entitlement Offer to any other person.

#### 5.11 **Notice to nominees and custodians**

The Retail Entitlement Offer is being made to all Eligible Retail Shareholders. Nominees with registered addresses in the eligible jurisdictions, irrespective of whether they participate under the Institutional Entitlement Offer, may also be able to participate in the Retail Entitlement Offer in respect of some or all of the beneficiaries on whose behalf they hold Existing Shares, provided that the applicable beneficiary would satisfy the criteria for an Eligible Retail Shareholder.

Nominees and custodians who hold Existing Shares as nominees or custodians will have received, or will shortly receive, a letter from PYC. Nominees and custodians should carefully consider the contents of that letter and note, in particular, that the Retail Entitlement Offer is not available to, and they must not purport to accept the Retail Entitlement Offer in respect of:

- (a) beneficiaries on whose behalf they hold Existing Shares who would not satisfy the criteria for an Eligible Retail Shareholder;
- (b) Eligible Institutional Shareholders who received an offer to participate in the Institutional Entitlement Offer (whether they accepted their Entitlement or not);
- (c) Ineligible Institutional Shareholders who were ineligible to participate in the Institutional Entitlement Offer; or
- (d) Shareholders who are not eligible under all applicable securities laws to receive an offer under the Retail Entitlement Offer.

In particular, persons acting as nominees for other persons may not take up Entitlements on behalf of, or send any documents relating to the Retail Entitlement Offer to, any person in the United States.

PYC is not required to determine whether or not any registered holder is acting as a nominee or the identity or residence of any beneficial owners of Shares. Where any holder is acting as a nominee for a foreign person, that holder, in dealing with its beneficiary, will need to assess whether indirect participation by the beneficiary in the Retail Entitlement Offer is compatible with the terms of the Retail Entitlement Offer and applicable foreign offer restrictions. In particular, without the consent of the Company, nominees and custodians may participate in the Retail Entitlement Offer only on behalf of beneficial holders with addresses in Australia and New Zealand who were not invited to participate in the Institutional Entitlement Offer.

## 5.12 Risks

Eligible Retail Shareholders should be aware that an investment in PYC involves risks. The key risks identified by PYC are set out in the 'Key risks' section of the Investor Presentation included in the Annexure.

## 5.13 Enquiries

If you have not received or you have lost your personalised Entitlement and Acceptance Form, or have any questions regarding the Entitlement Offer, please contact Automic Share Registry on 1300 288 664 (within Australia) or +61 2 9698 5414 (International) from 8.30am to 5.00pm (Sydney time) Monday to Friday during the Retail Entitlement Offer Period.

If you have any further questions, you should contact your stockbroker, solicitor, accountant or other professional advisor.

# 6 Additional Information

## 6.1 Eligibility of Retail Shareholders

The Retail Entitlement Offer is being offered to all Eligible Retail Shareholders only.

**Eligible Retail Shareholders** are those persons who:

- (a) are registered as holders of Existing Shares as at 4.00pm Perth time on the Record Date (being, Monday, 18 March 2024);
- (b) have a registered address recorded on PYC's share register in Australia or New Zealand;
- (c) are not in the United States and are not a person (including nominees or custodians) acting for the account or benefit of a person in the United States;
- (d) were not invited to participate in the Institutional Entitlement Offer and were not treated as Ineligible Institutional Shareholder under the Institutional Entitlement Offer; and
- (e) are eligible under all applicable securities laws to receive an offer under the Retail Entitlement Offer without any requirement for a prospectus or other disclosure document to be lodged or registered.

Retail shareholders who do not satisfy the above criteria are Ineligible Retail Shareholders.

By making a payment by either BPay® or EFT, you will be taken to have represented and warranted that you satisfy each of the criteria listed above to be an Eligible Retail Shareholder. Nominees, trustees or custodians are therefore advised to seek independent professional advice as to how to proceed.

PYC has determined that it is unreasonable to extend the Retail Entitlement Offer to Ineligible Retail Shareholders because of the small number of such Shareholders, the number and value of Shares that they hold and the cost of complying with the applicable regulations in jurisdictions outside Australia and New Zealand.

However, in accordance with section 615 of the Corporations Act, PYC has appointed Euroz Hartleys Limited as its ASIC-approved nominee (the **Nominee**) to arrange for the

sale on ASX of the New Shares which represent the full entitlement of Ineligible Institutional Shareholders and Ineligible Retail Shareholders (**Sale Shares**). The Nominee will be required to direct the net proceeds (if any, after deduction of the Offer Price, and costs of sale including brokerage and commission, if any (**Selling Fees**)) to the Share Registry to facilitate pro rata payments of any net proceeds to Ineligible Institutional Shareholders and Ineligible Retail Shareholders.

The Sale Shares will be issued at the same time as the issue of shares under the Retail Entitlement Offer.

The Nominee will be instructed to sell the Sale Shares on a best endeavours basis as soon as practicable following issue of the Sale Shares.

The proceeds of sale (if any) will be paid in Australian dollars to the Ineligible Institutional Shareholders and Ineligible Retail Shareholders for whose benefit the Sale Shares have been sold in proportion to their shareholdings (after deducting the Selling Fees).

Notwithstanding that the Nominee may sell Sale Shares, Ineligible Institutional Shareholders and Ineligible Retail Shareholders may nevertheless receive no net proceeds if the Offer Price plus the Selling Fees is greater than the sale proceeds.

If any such net proceeds of sale are less than the reasonable costs that would be incurred by PYC for distributing those proceeds, such proceeds may be retained by PYC.

Neither PYC nor the Nominee will be liable for a failure to obtain any net proceeds, or to sell Sale Shares at any particular price.

## 6.2 **Ranking of New Shares**

The New Shares issued under the Retail Entitlement Offer will be fully paid and rank equally with Existing Shares.

## 6.3 **Allotment**

PYC has applied for quotation of the New Shares on ASX in accordance with ASX Listing Rule requirements. If ASX does not grant quotation of the New Shares, PYC will repay all Application Monies (without interest).

Trading of New Shares will, subject to ASX approval, occur shortly after allotment. It is expected that allotment of the New Shares under the Retail Entitlement Offer will take place on 15 April 2024 (unless extended). Application Monies will be held by PYC on trust for Applicants until the New Shares are allotted. No interest will be paid on Application Monies.

Subject to approval being granted, it is expected that the New Shares allotted under the Retail Entitlement Offer will commence trading on a normal basis on 16 April 2024 (unless extended).

It is the responsibility of Applicants to determine the number of New Shares allotted and issued to them prior to trading in the New Shares. The sale by an Applicant of New Shares prior to receiving their holding statement is at the Applicant's own risk.

## 6.4 Reconciliation

The Entitlement Offer is a complex process and in some instances investors may believe they own more Shares than they actually do or are otherwise entitled to more New Shares than initially offered to them. These matters may result in a need for reconciliation. If reconciliation is required, it is possible that PYC may need to issue a small quantity of additional New Shares to ensure all Eligible Shareholders receive their appropriate allocation of New Shares up to their full Entitlement. The price at which these additional New Shares would be issued, if required, is the Offer Price.

PYC also reserves the right to reduce the size of an Entitlement or number of New Shares allocated to Eligible Retail Shareholders, or persons claiming to be Eligible Retail Shareholders or other applicable investors, if PYC believes in its complete discretion that their Entitlement claims are overstated or if they or their nominees fail to provide information requested to substantiate their claims. If necessary, the relevant shareholder may need to transfer existing Shares held by them or to purchase additional Shares on-market to meet this obligation. The relevant Shareholder will bear any and all losses caused by subscribing for New Shares in excess of their Entitlement and any actions they are required to take in this regard.

By applying under the Retail Entitlement Offer, those doing so irrevocably acknowledge and agree to do the above as required by PYC in its absolute discretion. Those applying acknowledge that there is no time limit on the ability of PYC to require any of the actions set out above.

## 6.5 Capital structure on completion of the Entitlement Offer

The proposed capital structure of the Company following the issue of the New Shares under the Entitlement Offer, assuming full take-up, will be as follows:

Shares	Number
Existing Shares currently on issue at the Record Date <sup>1</sup>	3,732,867,135
Maximum number of New Shares offered pursuant to Entitlement Offer	933,216,784
<b>Total Shares on issue after completion of the Entitlement Offer<sup>1</sup></b>	<b>4,666,083,919</b>

### Notes:

1. The above figures assume that no existing options over Shares will be exercised prior to the Record Date. At the date of this Retail Offer Booklet, the Company has 31,600,000 options for new fully paid ordinary Shares outstanding with a collective weighted average exercise price of \$0.174 (and individual exercise prices ranging from \$0.09 to \$0.21). No Shares or Options on issue are subject to escrow restrictions, either voluntary or ASX imposed.

## 6.6 Potential Dilution Effect

You should note that if you do not participate in the Entitlement Offer, your holdings may be diluted by as much as approximately 20% (after taking into account dilution following completion of the Entitlement Offer).

The following are examples of how any dilution may impact you if you do not participate in the Entitlement Offer, assuming the maximum number of New Shares are issued:

Example Shareholder	# Existing Shares at Record Date	% at Record Date	Entitlement	# Shares if Entitlement declined	% after issue of New Shares
Shareholder 1	50,000,000	1.34%	12,500,000	50,000,000	1.07%
Shareholder 2	40,000,000	1.07%	10,000,000	40,000,000	0.86%
Shareholder 3	10,000,000	0.27%	2,500,000	10,000,000	0.21%
Shareholder 4	5,000,000	0.13%	1,250,000	5,000,000	0.11%

### Notes:

- The table assumes that no Shares are issued other than under the Entitlement Offer.
- The dilution effect shown in the table is the maximum percentage of dilution on the assumption that the Offer is fully subscribed. If the Retail Entitlement Offer is not fully subscribed, the dilution effect for each Shareholder not accepting their Entitlement would be a lesser percentage.

## 6.7 Details of substantial shareholders

As at the Record Date, Company has the following substantial holders (based on the substantial holder notices received by the Company and released to the ASX):

Substantial holders of the Company	No. of Shares <sup>1</sup>	Voting Power
Australian Land Pty Ltd (and associates)	1,229,813,974	32.95%
David Sietsma (and associates)	288,275,006	7.72%
Malcolm McCusker (and associates)	180,250,000	5.6%

**Notes:** 1. The Table does not include the proposed issue of New Shares under the Institutional Entitlement Offer.

## 6.8 Possible control implications

The potential effect of the issue of New Shares on control of the Company, and the consequences of that effect, will depend on a number of factors, including investor demand and the extent to which eligible shareholders take up their entitlements under the Entitlement Offer. Shareholders should note that if they do not participate in the Entitlement Offer, their holdings are likely to be diluted.

Under section 606 of the Corporations Act, a person cannot acquire a relevant interest in the issued voting shares of a company if, because of a transaction in relation to securities of that company, a person's voting power in the company increase from 20% or below to more than 20% (or from a starting point that is above 20% and below 90%).

There are certain exceptions to the above prohibition in section 606 of the Corporations Act. Item 10A of the table in section 611 (as notionally inserted by ASIC Corporations (Takeovers – Accelerated Rights Issues) Instrument 2015/1069 (**Item 10A Exception**)) provides an exception for an acquisition of securities pursuant to a rights issue. If the Item 10A Exception is to be relied upon then section 615 of the Corporations Act (regarding the appointment of a nominee for the sale of the New Shares which represent the full entitlement of Ineligible Institutional Shareholders and Ineligible Retail Shareholders) must be complied with, which includes a requirement for ASIC to approve the nominee. As detailed in section 6.1, the Company has appointed Euroz Hartleys Limited as its Nominee and this appointment has been approved by ASIC.

### ***Major Shareholder participation***

As described above, Chairman Mr Alan Tribe represents PYC's major shareholder through Australian Land Pty Ltd and its associates (collectively, **Australian Land**) with voting power of 32.95% immediately before the Entitlement Offer.

Under the Institutional Entitlement Offer, the total of New Shares to be issued under the Institutional Entitlement Offer is 500,000,000 New Shares raising approximately \$40 million (before costs). All substantial shareholders listed in 6.7 were accelerated with two of the three substantial shareholders taking up either all or part of their Entitlements.

Australian Land committed to take up its full Entitlement of 307,453,493 New Shares for a total Offer Price of \$24,596,279. McCusker committed a further \$1 million representing 12,500,000 New Shares.

On the completion of the Institutional Entitlement Offer, Australian Land is expected to have a total shareholding of 1,537,267,467 Shares and as such have voting power in PYC of approximately 36.32%.

Whilst the voting power of Australian Land immediately following the completion of the Institutional Entitlement Offer will increase to approximately 36.32%, immediately following the completion of the Retail Entitlement Offer, Australian Land's voting power will reduce to approximately 32.95% (assuming the maximum number of shares are issued under the Retail Entitlement Offer).

The following table shows the potential change in Australian Land's voting power based on different assumptions on acceptance of the Retail Entitlement Offer.

<b>% Acceptance</b>	<b>New Shares issued under Retail Entitlement Offer</b>	<b>Company's issued Shares (post Entitlement Offer)</b>	<b>Australian Land's Voting Power</b>
100%	433,216,784	4,666,083,919	32.95%
75%	324,912,588	4,557,779,723	33.73%
50%	216,608,392	4,449,475,527	34.55%
25%	108,304,196	4,341,171,331	35.41%
0%	0	4,232,867,135	36.32%

For further information on the potential effect of the Entitlement Offer, please refer to the Company's cleansing notice that was released to ASX on 14 March 2024 (before the results of the Institutional Entitlement Offer were known).

## 6.9 **Taxation**

There may be tax consequences for Shareholders who decide to participate in the Retail Entitlement Offer and receive New Shares. The Company does not consider that it is appropriate to give advice regarding the taxation consequences of applying for New Shares under the Retail Entitlement Offer. The taxation consequences will depend on the circumstances of each Applicant. Applicants should consult their own professional adviser in connection with the taxation implications of subscribing for New Shares offered in the Retail Entitlement Offer.

## 6.10 **Continuous disclosure**

PYC is a "disclosing entity" under the Corporations Act and is subject to regular reporting and disclosure obligations under the Corporations Act and ASX Listing Rules, including the preparation of annual reports and half yearly reports.

PYC is required to notify ASX of information about specific events and matters as they arise for the purposes of ASX making that information available to the stock markets conducted by ASX. In particular, PYC has an obligation under the ASX Listing Rules (subject to certain exceptions) to notify ASX immediately of any information of which it is or becomes aware which a reasonable person would expect to have a material effect on the price or value of PYC shares.

That information is available to the public from ASX.

### 6.11 **No cooling off rights**

Cooling off rights do not apply to an investment in New Shares. You cannot withdraw your Application once it has been accepted.

### 6.12 **Not investment advice**

This Retail Offer Booklet is not a prospectus under the Corporations Act and has not been lodged with ASIC. It is also not financial product advice and has been prepared without taking into account your investment objectives, financial circumstances or particular needs. PYC is not licensed to provide financial product advice in respect of the New Shares.

The information contained in this Retail Offer Booklet does not purport to contain all the information that you may require to evaluate a possible application for New Shares, nor does it purport to contain all the information which would be required in a prospectus prepared in accordance with the requirements of the Corporations Act. It should be read in conjunction with PYC's other periodic statements and continuous disclosure announcements lodged with ASX.

### 6.13 **Privacy**

The Company collects information about each Applicant provided on an Entitlement and Acceptance Form for the purposes of processing the Application and, if the Application is successful, to administer the Applicant's security holding in the Company.

By submitting an Entitlement and Acceptance Form, each Applicant agrees that the Company may use the information provided by an Applicant on the Entitlement and Acceptance Form for the purposes set out in this Retail Offer Booklet and may disclose it for those purposes to the Share Registry, the Company's related bodies corporate, agents, contractors and third party service providers, including mailing houses and professional advisers, and to ASX and regulatory authorities.

If you do not provide the information required on the Entitlement and Acceptance Form, the Company may not be able to accept or process your Application. An Applicant has a right to gain access to the information that the Company holds about that person subject to certain exemptions under law. A fee may be charged for access. Access requests must be made in writing to the Company's registered office.

### 6.14 **Jurisdiction**

This Retail Offer Booklet (including the Entitlement and Acceptance Form) and the contracts that arise from the acceptance of the Applications are governed by the laws applicable in Western Australia and each Applicant submits to the non-exclusive jurisdiction of the courts of Western Australia.

### 6.15 **Foreign jurisdictions**

This Retail Offer Booklet does not constitute an offer of New Shares in any jurisdiction in which it would be unlawful. In particular, this Retail Offer Booklet may not be distributed to any person, and the New Shares may not be offered or sold, in any country outside Australia except to the extent permitted below.

#### **New Zealand**

The New Shares are not being offered to the public within New Zealand other than to existing shareholders of the Company with registered addresses in New Zealand to whom the offer of these securities is being made in reliance on the Financial Markets Conduct (Incidental Offers) Exemption Notice 2021.

This Retail Offer Booklet has been prepared in compliance with Australian law and has not been registered, filed with or approved by any New Zealand regulatory authority under the Financial Markets Conduct Act 2013. This Retail Offer Booklet is not a product disclosure statement under New Zealand law and is not required to, and may not, contain all the information that a product disclosure statement under New Zealand law is required to contain.

## 7 Glossary

In this Retail Offer Booklet, unless the context requires otherwise:

Term	Meaning
<b>\$ or A\$ or AUD or dollars</b>	Australian dollar.
<b>Applicant</b>	an Eligible Retail Shareholder who submits a valid Application.
<b>Application</b>	an application to subscribe for New Shares under the Retail Entitlement Offer.
<b>Application Monies</b>	application monies for New Shares received by the Company from an Applicant.
<b>ASIC</b>	Australian Securities & Investments Commission.
<b>ASX</b>	ASX Limited (ABN 98 008 624 691) or the financial products market operated by that entity known as the Australian Securities Exchange.
<b>ASX Announcement</b>	the announcement released to ASX on 14 March 2024 in connection with the Entitlement Offer, a copy of which is set out in the Annexure.
<b>ASX Listing Rules</b>	the official ASX Listing Rules of ASX, as amended or replaced from time to time and as waived in respect of PYC by ASX.
<b>Australian Land</b>	Mr Alan Tribe, Australian Land Pty Ltd and their respective associates who are Shareholders.
<b>Board</b>	the board of directors of PYC.
<b>Company or PYC</b>	PYC Therapeutics Limited ACN 098 391 961.
<b>Constitution</b>	the constitution of the Company as at the date of this Retail Offer Booklet.
<b>Corporations Act</b>	<i>Corporations Act 2001</i> (Cth).
<b>EFT</b>	Electronic Funds Transfer.

<b>Term</b>	<b>Meaning</b>
<b>Eligible Institutional Shareholder</b>	a person who: <ul style="list-style-type: none"> <li>(a) was identified as an Institutional Shareholder by PYC;</li> <li>(b) has a registered address in Australia or New Zealand;</li> <li>(c) is not in the United States and is not acting for the account or benefit of a person in the United States;</li> <li>(d) is a sophisticated or professional investor in Australia in accordance with sections 708(8) to section 708(11) of the Corporations Act or a wholesale investor in New Zealand and, as such, is eligible under all applicable securities laws to receive an offer under the Institutional Entitlement Offer; and</li> <li>(e) who has successfully received an offer under the Institutional Entitlement Offer.</li> </ul>
<b>Eligible Retail Shareholder</b>	is defined in Section 6.1.
<b>Eligible Shareholder</b>	a person who is an Eligible Institutional Shareholder or an Eligible Retail Shareholder.
<b>Entitlement</b>	the entitlement to subscribe for 1 New Share for every 4 Existing Shares held on the Record Date by Eligible Shareholders.
<b>Entitlement and Acceptance Form</b>	the Entitlement and Acceptance Form accompanying this Retail Offer Booklet.
<b>Entitlement Offer</b>	the Institutional Entitlement Offer and the Retail Entitlement Offer.
<b>Excess Amount</b>	is defined in Section 5.4.
<b>Existing Share</b>	a Share on issue before the Record Date.
<b>Indicative Timetable</b>	the indicative timetable set out in Section 2 (as varied by the Company).
<b>Ineligible Institutional Shareholder</b>	an Institutional Shareholder who is not an Eligible Institutional Shareholder.
<b>Ineligible Retail Shareholder</b>	a Shareholder who is neither an Institutional Shareholder nor an Eligible Retail Shareholder.
<b>Institutional Entitlement Offer</b>	the accelerated non-renounceable pro-rata entitlement offer to Eligible Institutional Shareholders.

<b>Term</b>	<b>Meaning</b>
<b>Institutional Investor</b>	a person: <ul style="list-style-type: none"> <li>(a) in Australia, to whom an offer of securities in a company may be made in Australia without a disclosure document (as defined in the Corporations Act) on the basis that such a person is an 'exempt investor' as defined section 9A(5) of the Corporations Act (as inserted by ASIC Corporations (<i>Non-Traditional Rights Issues</i>) Instrument 2016/84); or</li> <li>(b) in selected jurisdictions outside Australia to whom an offer of New Shares may be made without registration, lodgement of a formal disclosure document or other formal filing in accordance with the laws of that foreign jurisdiction (except to the extent to which PYC, at its absolute discretion, is willing to comply with such requirements).</li> </ul>
<b>Institutional Shareholder</b>	a Shareholder on the Record Date who is an Institutional Investor.
<b>Investor Presentation</b>	the presentation released to ASX on 14 March 2024 in connection with the Entitlement Offer, a copy of which is set out in the Annexure.
<b>New Shares</b>	the Shares to be allotted and issued under the Entitlement Offer or this Booklet.
<b>Offer Price</b>	\$0.08 per New Share.
<b>Record Date</b>	the time and date for determining which Shareholders are entitled to an Entitlement under the Entitlement Offer, being 4.00pm Perth time on 18 March 2024.
<b>Retail Closing Date</b>	4.00pm Perth time on 8 April 2024 (unless extended). This is the final date that Eligible Retail Shareholders can take up some or all of their Entitlement.
<b>Retail Offer Booklet</b>	this booklet dated 20 March 2024, including the ASX Announcement and Investor Presentation.
<b>Retail Offer Period</b>	the period commencing on the Retail Opening Date and ending on the Retail Closing Date.
<b>Retail Opening Date</b>	the opening date of the Retail Entitlement Offer as set out in the Indicative Timetable.
<b>Section</b>	a section of this Retail Offer Booklet.
<b>Share</b>	a fully paid ordinary PYC share.

Term	Meaning
<b>Shareholder</b>	the registered holder of an Existing Share.
<b>Share Registry</b>	PYC's share registry, being Automic Group of Level 5, 191 St Georges Terrace, Perth, Western Australia 6000 or any other person appointed as registry by PYC from time to time.
<b>Shortfall</b>	is defined in Section 4.5.
<b>Shortfall Shares</b>	is defined in Section 4.5.
<b>U.S. or United States</b>	has the meaning given to that term in Rule 902(l) under the U.S. Securities Act
<b>US Securities Act</b>	the US Securities Act of 1933, as amended.

## Corporate Directory

### Directors

**Mr Alan Tribe**

Non-Executive Director and Chairperson

**Dr Rohan Hockings**

Executive Director & Chief Executive Officer

**Dr Michael Rosenblatt**

Non-Executive Director

**Mr Jason Haddock**

Non-Executive Director

### Company secretary

**Mr Andrew Taylor & Mr Kevin Hart**

### Registered office

Office 4, Level 1  
174 Hampden Road  
NEDLANDS WA 6009

Telephone: +61 8 9316 9100  
Facsimile: +61 8 9315 5475

### Postal address

Office 4, Level 1  
174 Hampden Road  
NEDLANDS WA 6009

### Principal place of business

Harry Perkins Institute  
6 Verdun Street  
NEDLANDS WA 6009  
Telephone: +61 8 6151 0992  
Facsimile: +61 8 9315 5475

### Share registry

#### Automatic Group

Level 5, 191 St Georges Terrace  
Perth Western Australia 6000

Telephone within Australia: 1300 228 664  
Telephone outside Australia: +61 2 8072 1400

### Auditor

#### Pricewaterhouse Coopers

Level 15  
125 St Georges Terrace  
Perth Western Australia 6000

### Stock exchange listing

PYC Therapeutics Limited shares are listed on the Australian Securities Exchange (ASX code: PYC)

Incorporated in Western Australia, October 2001

### Website

[www.pyctx.com](http://www.pyctx.com)



**PYC**  
Therapeutics

## **Annexure ASX Announcements**

This Annexure contains copies of the Company's following ASX announcements:

- **ASX Announcement** – PYC Therapeutics Limited to Raise up to ~\$74.6 million via an Accelerated Non-Renounceable Entitlement Offer dated 14 March 2024
- **Investor Presentation** - *\$75m capital raising to drive human data read-outs* (March 2024)
- *Completion of Institutional Entitlement Offer* dated 18 March 2024

*NOT FOR RELEASE TO US WIRE SERVICES OR DISTRIBUTION IN THE UNITED STATES*

## **PYC THERAPEUTICS LIMITED TO RAISE UP TO ~\$74.6 MILLION VIA AN ACCELERATED NON-RENOUNCEABLE ENTITLEMENT OFFER**

- PYC Therapeutics to raise up to approximately \$74.6 million via a 1 for 4 pro-rata accelerated non-renounceable entitlement offer
- New Shares to be issued at A\$0.08 per share, representing a 5.9% discount to the last traded price
- Proceeds from the equity raising will be used to fund progression of the Company's pipeline of first-in-class drug candidates for patients with major unmet needs through critical human data readouts
- Major shareholder Australian Land Pty Ltd, representing ~32.95% of PYC's issued capital, has indicated that they intend to take up their full entitlement - accounting for approximately \$24.6 million of the Entitlement Offer

### **PERTH, Australia– 14 March 2024**

PYC Therapeutics Limited (ASX:PYC) (**PYC** or the **Company**) today announces that it is undertaking a pro-rata accelerated non-renounceable entitlement offer to eligible shareholders on the basis of one (1) new share for every four (4) existing shares held which is intended to raise approximately A\$74.6 million (before costs) (**Entitlement Offer**).

The Entitlement Offer will comprise the issue of up to approximately 933 million new fully paid ordinary shares in PYC (**New Shares**) at an offer price of \$0.08 (**Offer Price**) per New Share, which represents a:

- 5.9% discount to the last traded price of A\$0.085 on 13 March 2024;
- 4.8% discount to the Theoretical Ex-Rights Price (**TERP**)<sup>1</sup> of A\$0.084 per share; and

---

<sup>1</sup> The theoretical ex-rights price is the theoretical price at which PYC shares should trade immediately after the ex-date for the Entitlement Offer. The TERP is a theoretical calculation only and the actual price at which PYC's shares trade immediately after the ex-date for the Entitlement Offer will depend on many factors and may not equal the TERP. TERP is calculated by reference to PYC's closing price of A\$0.085 on 13 March 2024.

- 1.1% discount to the 5-day volume weighted average price of shares up to and including 13 March 2024.

The Entitlement Offer comprises:

- an accelerated institutional component open to eligible institutional shareholders to be conducted from Thursday, 14 March 2024 to Friday, 15 March 2024 (**Institutional Entitlement Offer**); and
- a retail component open to eligible retail shareholders in Australia or New Zealand anticipated to be conducted from Wednesday, 20 March 2024 to Monday, 8 April 2024 (unless extended) (**Retail Entitlement Offer**).

The offer ratio and Offer Price for New Shares under the Retail Entitlement Offer are the same as for the Institutional Entitlement Offer.

The Entitlement Offer is not underwritten and as such there is no guarantee that PYC will raise the intended amount of ~\$74.6 million in which case PYC will need to re-evaluate its fundraising options and/or its projected budget and timeline.

### **Use of funds**

The proceeds from the Entitlement Offer will be used to:

- progress PYC's first blinding eye disease drug candidate into mid and late-stage human trials
- progress PYC's second blinding eye disease drug candidate into early and mid-stage human trials
- progress PYC's polycystic kidney disease drug candidate into human trials
- support progression of the Company's Phelan-McDermid Syndrome drug program and drug discovery activities
- general working capital and Entitlement Offer costs

As outlined above, the Entitlement Offer is not underwritten. If the proceeds from the Entitlement Offer are less than what is required to meet the Company's proposed use of funds, the Company may review its proposed use of funds (including whether to scale back or defer investments) as well as consider alternative funding options.

Commenting on the Entitlement Offer, PYC's CEO, Dr Rohan Hockings said:

"An entitlement offer provides all shareholders with an equal opportunity to contribute to the further progression of PYC's exciting drug development pipeline. The rapidly improving conditions in the biotech sector coupled with the material progress made by the Company have not yet been recognised in PYC's market capitalisation. PYC is seeking to address this by delivering human safety and efficacy data – the currency of our industry – over the coming 12 months alongside progression of ongoing commercialisation activities".

Further details of the Entitlement Offer are set out below.

## Entitlement Offer structure

Under the Entitlement Offer, eligible shareholders are invited to subscribe for one (1) New Share for every four (4) existing PYC shares held (**Entitlement**).

The Entitlement Offer is non-renounceable, and Entitlements will not be tradable or otherwise transferable.

Eligible shareholders who do not take up their Entitlement under the Entitlement Offer in full or in part, will not receive any value with respect to those Entitlements not taken up. New Shares issued under the Entitlement Offer will be fully paid and will rank equally with existing PYC shares at the time of issue.

## Institutional Entitlement Offer

Eligible institutional shareholders may be invited to participate in the Institutional Entitlement Offer which opens today, Thursday, 14 March 2024 and closes on Friday, 15 March 2024.

Under the Institutional Entitlement Offer, eligible institutional shareholders with a registered address in Australia and New Zealand (**Eligible Institutional Shareholders**) who are invited to participate in the Institutional Entitlement Offer can choose to take up all, or part or none of their Entitlements under the Entitlement Offer.

Shares in the Company have been placed in a trading halt while the Institutional Entitlement Offer is being undertaken. It is expected that the trading halt will end at market open on Monday, 18 March 2024.

New Shares under the Institutional Entitlement Offer are expected to be issued on Wednesday, 20 March 2024. PYC will, upon issue of the New Shares under the Institutional Entitlement Offer, seek quotation of the New Shares on the ASX.

## Retail Entitlement Offer

The Retail Entitlement Offer will be conducted at the same offer price and offer ratio as the Institutional Entitlement Offer.

Eligible retail shareholders with a registered address in Australia or New Zealand as at 4.00pm (AWST) on Monday, 18 March 2024 (**Record Date**) (**Eligible Retail Shareholders**) will have the opportunity to participate in the Retail Entitlement Offer.

Further information will be sent to Eligible Retail Shareholders in a retail offer book (**Retail Offer Booklet**). The Retail Offer Book will be sent to Eligible Retail Shareholders, along with accompanying personalised entitlement and acceptance forms, on or around Wednesday, 20 March 2024.

The Retail Entitlement Offer is currently expected to close on Monday, 8 April 2024.

Eligible Retail Shareholders can choose to take up all, or part or none of their Entitlement under the Entitlement Offer, on the terms and conditions set out in the Retail Offer Booklet.

New Shares under the Retail Entitlement Offer are expected to be issued on Monday, 15 April 2024. PYC will, upon issue of the New Shares under the Retail Entitlement Offer, seek quotation of the New Shares on the ASX.

Shareholders with a registered address outside Australia or New Zealand on the Record Date are ineligible to participate in the Retail Entitlement Offer.

The directors have reserved the right to place any shortfall within 3 months of close of the Entitlement Offer at the Board's discretion but at a price no less than the Offer Price.

### Nominee

The Company has appointed Euroz Hartleys Limited (**Nominee**) to act as a nominee for the purposes of section 615 of the *Corporations Act 2001* (Cth), who will arrange for the sale on ASX (or otherwise) of New Shares under the Entitlement Offer which would otherwise have been available to ineligible shareholders. The Nominee will be required to remit any net proceeds (if any, after deduction of the Offer Price, costs of sale including brokerage and costs) from the sale of those New Shares to those ineligible shareholders. There is no guarantee that any proceeds will be realised from the sale of the entitlements that would otherwise have been offered to ineligible shareholders.

### Key shareholder support

As described above, Chairman Alan Tribe via Australian Land has agreed to take up his full entitlement under the Entitlement Offer (representing approximately \$24.6 million). Please refer to PYC's cleansing notice released to ASX today in relation to the potential control effects of the Entitlement Offer.

### Indicative Timetable\*

Event	Timing (AWST)
Trading halt	Thursday, 14 March 2024
Announcement of Entitlement Offer	Thursday, 14 March 2024
<b>Institutional Entitlement Offer opens</b>	<b>Thursday, 14 March 2024</b>
<b>Institutional Entitlement Offer closes</b>	<b>4.00pm (AWST) Friday, 15 March 2024</b>
Announcement of results of Institutional Entitlement Offer Trading halt lifted, existing securities commence trading	Monday 18 March 2024
Record Date for Entitlement Offer	4.00pm (AWST) on Monday, 18 March 2024
Settlement of New Shares under Institutional Entitlement Offer	Tuesday, 19 March 2024

Quotation of New Shares issued under the Institutional Entitlement Offer and commencement of trading of such securities on the ASX	Wednesday, 20 March 2024
<b>Retail Entitlement Offer Opens (Retail Offer Booklet sent)</b>	<b>Wednesday, 20 March 2024</b>
Last day to extend retail offer close date (if required)	<b>Wednesday, 3 April 2024</b>
<b>Retail Entitlement Offer Closes</b>	<b>Monday, 8 April 2024</b>
Announcement of results of Retail Entitlement Offer	Wednesday, 10 April 2024
Allotment and issue of New Shares under Retail Entitlement Offer	Monday, 15 April 2024
New Shares under Retail Entitlement Offer commence trading on ASX	Tuesday, 16 April 2024
Holding statements sent for New Shares issued under the Retail Entitlement Offer	Wednesday, 17 April 2024

\*The timetable above is indicative only and subject to change. The Company reserves the right to alter the dates below in its full discretion and without prior notice, subject to the ASX Listing Rules and the Corporations Act.

**This ASX announcement has been authorised for release by the Board of PYC Therapeutics Limited.**

### About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. PYC's drug development programs target monogenic diseases – **the indications with the highest likelihood of success in clinical development**<sup>2</sup>.

The Company was the first to progress a drug candidate for a blinding eye disease of childhood into human trials. The Company is progressing a second blinding eye disease (Autosomal Dominant Optic Atrophy) and a third program targeting Polycystic Kidney Disease which are anticipated to commence human trials in mid-2024 and late 2024 respectively.

For more information, visit [pyctx.com](https://pyctx.com), or follow us on LinkedIn and Twitter.

<sup>2</sup> Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank  
<https://doi.org/10.1101/2020.11.02.20222232>

## **Forward looking statements**

*Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations, and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations, and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.*


*This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.*

*This ASX announcement was approved and authorised for release by the Board of PYC Therapeutics Limited*

### **CONTACTS:**

#### **INVESTORS and MEDIA**

info@pyctx.com



# PYC Therapeutics

Life-changing science

\$75m capital raising to drive human data read-outs

March 2024



# Important Notices

## **Important Information & Disclaimer**

You must read the following notices before reading or making any use of this document or any information contained in this document. By continuing to read, use or otherwise act on this document, you agree to be bound by the following terms and conditions, including any modifications to them.

This presentation (Presentation) has been prepared by PYC Therapeutics Limited (ACN 098 391 961) (ASX:PYC) (Company or PYC) in relation to its proposed pro-rata accelerated non-renounceable entitlement offer of new PYC shares (New Shares) to be made to eligible institutional shareholders of PYC (Institutional Entitlement Offer) and eligible retail shareholders of PYC (Retail Entitlement Offer) under section 708AA of the Corporations Act 2001 (Cth) (Corporations Act) as modified by ASIC Corporations (Non-Traditional Rights Issues) Instrument 2016/84 (Entitlement Offer or Equity Raising).

## **Summary information**

This Presentation contains summary information about the Company and its activities current as at 13 March 2024. The information in this Presentation is of a general nature and does not purport to be complete nor does it contain all information which a prospective investor may require in evaluating a possible investment in the Company or that would be required in a prospectus or product disclosure statement prepared in accordance with the requirements of the Corporations Act. The historical information in this Presentation is, or is based on, information that has been released to the ASX. This Presentation should be read in conjunction with the Company's other periodic and continuous disclosure announcements lodged with the ASX, which are available at [www.asx.com.au](http://www.asx.com.au).

Any market and industry data that may be used in connection with this Presentation may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. None of the Company, its representatives or advisers have independently verified that market or industry data provided by third parties or industry or general publications.

Statements made in this Presentation are made only as at the date of this Presentation. The information in this Presentation remains subject to change without notice. The Company reserves the right to withdraw the Equity Raising or vary the timetable for the Equity Raising without notice.

## **Not an offer**

This Presentation is not an offer or invitation to acquire New Shares or any other financial products and is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This Presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. This Presentation is not and should not be considered an offer or an invitation to acquire the New Shares or any other financial products and does not and will not form any part of any contract for the acquisition of the New Shares.

# Important Notices

---

## **Not financial product advice**

This Presentation does not constitute financial product or investment advice or any recommendation to acquire New Shares or accounting, legal or tax advice. It has been prepared without taking into account the objectives, financial or tax situation or needs of individuals. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial and tax situation and needs and obtain legal and taxation advice appropriate to their jurisdiction. PVC is not licensed to provide financial product advice in respect of the New Shares or any other financial products. Cooling off rights do not apply to the acquisition of New Shares under the Equity Raising.

## **Investment risk**

An investment in the New Shares is subject to investment and other known and unknown risks, some of which are beyond the control of PVC including loss of income and principal invested. The Company does not guarantee any particular rate of return or performance or any particular tax treatment. Persons should have regard to the risk factors detailed in Appendix A of this Presentation.

## **Effect of rounding**

A number of figures, amounts, percentages, estimates and calculations of value in this Presentation are subject to the effect of rounding.

## **Past performance**

Investors should note that past performance and pro forma financial information given in this Presentation is given for illustrative purposes only and should not be relied on as (and is not) an indication of PVC's views on its future financial performance or condition. Prospective investors should note that past performance, including past share price performance, of PVC cannot be relied on as an indicator of (and provides no guidance as to) future performance including future share price performance. The historical information in relation to PVC included in this Presentation is, or is based on, information that has previously been released to the market.

## **Forward-looking statements and aspirational targets**

Some statements in this Presentation regarding estimates or future events are forward-looking statements. They include indications of, and guidance on, future matters. Forward-looking statements include, but are not limited to, statements preceded by words such as "planned", "expected", "projected", "anticipated", "intends", "scheduled", "may", "anticipates", "believes", "potential", "could", "nominal", "conceptual" and similar expressions. Forward-looking statements, opinions and estimates included in this Presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions.

# Important Notices

Forward-looking statements are provided as a general guide only and should not be relied on as a guarantee of future performance. Forward-looking statements may be affected by a range of variables and risks that could cause actual results to differ from anticipated results and may cause PYC's actual performance and results (and other forward-looking statements) to materially differ from any projections of future performance or results expressed or implied by such forward-looking statements. Readers should not place undue reliance on such forward-looking information. There can be no assurance that forward-looking statements will prove to be correct. This Presentation may include aspirational targets. These targets are based on management's expectations and beliefs concerning future events as of the time of the release of this Presentation. Targets are necessarily subject to risks, uncertainties and other factors, some of which are outside the control of PYC that could cause actual results to differ materially from such statements.

## **No Liability**

The information contained in this document has been prepared in good faith by PYC. However, no guarantee, representation or warranty expressed or implied is or will be made by any person (including PYC and its affiliates and their directors, officers, employees, associates, advisers and agents) as to the accuracy, reliability, correctness, completeness or adequacy of any statements, estimates, options, conclusions or other information contained in this document. To the maximum extent permitted by law, PYC and its affiliates and their directors, officers, employees, associates, advisers and agents each expressly disclaims any and all liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of or reliance on information contained in this document including representations or warranties or in relation to the accuracy or completeness of the information, statements, opinions, forecasts, reports or other matters, express or implied, contained in, arising out of or derived from, or for omissions from, this document including, without limitation, any financial information, any estimates or projections and any other financial information derived therefrom.

Statements in this document are made only as of the date of this document unless otherwise stated and the information in this document remains subject to change without notice. No responsibility or liability is assumed by PYC or any of its affiliates for updating any information in this document or to inform any recipient of any new or more accurate information or any errors or omissions of which PYC and any of its affiliates or advisers may become aware.

## **Determination of eligibility of investors**

Determination of eligibility of investors for the purposes of the Entitlement Offer is determined by reference to a number of matters, including legal and regulatory requirements, logistical and registry constraints and the discretion of the Company. To the maximum extent permitted by law, Company (including its officers, agents and employees) each disclaim any duty or liability (including, without limitation, any liability arising from fault, negligence or negligent misstatement) in respect of the exercise of that discretion or otherwise. The Company may rely on information provided by or on behalf of institutional investors in connection with managing, conducting or underwriting the Entitlement Offer without the Company having independently verified that information and the Company do not assume responsibility for the fairness, currency, accuracy, timeliness, reliability or completeness of the information (including the accuracy, likelihood of achievement or reasonableness of any forecast returns, yields, future income or other statements in relation to future matters nor that the Information or this website contains all material information about PYC or which a prospective investor may require in evaluating a possible investment in PYC).

# Important Notices

---

## **Industry data**

Certain market and industry data used in connection with this Presentation, including in relation to other companies in PYC's peer group, may have been obtained from public filings, research, surveys or studies conducted by third parties, including industry or general publications. Neither the Company nor its advisors or representatives have independently verified any such market or industry data provided by third parties or industry or general publications.

## **Trademarks**

This Presentation may contain trademarks, trade names and copyrights of other companies, which are the property of their respective owners. Solely for convenience, some of the trademarks, trade names and copyrights referred to in this Presentation may be listed without the © or ® symbols, but PYC asserts, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, trade names and copyright.

## **International selling restrictions**

This Presentation does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in any jurisdiction. The distribution of this presentation and the offer of securities is restricted in jurisdictions outside Australia. See Appendix B of this Presentation for more information. Any failure to comply with such restrictions could constitute a violation of applicable securities laws. In particular, this Presentation may not be released to US wire services or distributed in the United States. This Presentation has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This Presentation does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this Presentation have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws.


By accepting this Presentation you represent and warrant that you are entitled to receive the Presentation in accordance with these restrictions and agree to be bound by their limitations.

# Corporate Structure



Capital structure pre-raise <sup>1</sup>	
Shares on issue	3,733 million
Market capitalisation	\$317.3 million
Cash at bank	\$25.4 million
Debt	Nil
Enterprise value	\$291.9 million

Shareholders pre-raise <sup>2</sup>	Percent held
Australian Land Pty Ltd	32.95%
David Sietsma	7.72%
Malcolm McCusker	5.67%



Board of Directors	
Alan Tribe	Non-Executive Chairman
Rohan Hockings	Managing Director
Michael Rosenblatt	Non-Executive Director
Jason Haddock	Non-Executive Director

1. Shares on issue 3,732,867,135; market capitalisation as at 13 March 2024; cash at bank as at 1 January 2024

2. Holdings accurate as at 12 October 2023 – PYC Annual Report 2023

# PYC Therapeutics – a clinical stage drug development company

- With first-in-class assets
- Dedicated to patients who have no treatment options available today
- Developing drugs with the highest probability of success in the clinic<sup>1</sup>
- In commercially attractive markets (\$1 to 10 billion per asset per annum<sup>2</sup>)
- Funding to deliver multiple human data catalysts over the next 24 months<sup>3</sup>

1. Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank. doi: <https://doi.org/10.1101/2020.11.02.20222232>

2. Market size is projected by multiplying patient prevalence per indication by the median orphan drug price of \$150k p.a. EvaluatePharma. Orphan Drug Report. 2019. Refer to slide 31 for prevalence references

3. Based on management forecasts as at 13 March 2024 and subject to successful completion of the Entitlement Offer all of the risks outlined in Appendix A

## Equity raise structure

- A pro rata Entitlement Offer to all shareholders
- At a single-digit discount to the last-traded price
- To fund major technical milestones (human safety and efficacy) across multiple pipeline assets<sup>1</sup>
- In the context of an improving macro environment for biotechnology<sup>2</sup>
- Supported by the Company's major shareholder<sup>3</sup>

1. Based on management forecasts as at 13 March 2024 and subject to successful completion of the Entitlement Offer and all of the risks outlined in Appendix A

2. <https://endpts.com/is-the-biotech-market-rally-real-data-suggest-comeback-in-private-public-markets/>

3. Australian Land Pty Ltd will take up its full entitlement of the offer – see ASX announcement of 14 March 2024

# Funding PYC through multiple major milestones<sup>1</sup>

2024

2025



## Program



### **RP11** **VP-001**

Monogenic blinding eye disease of childhood  
Prevalence: 1 in 100,000<sup>2</sup>



### **ADPKD** **PYC-003**

Most common lethal single-gene disorder in the world  
Prevalence: 1 in 1,000<sup>2</sup>



### **ADOA** **PYC-001**

Monogenic blinding eye disease of childhood  
Prevalence: 1 in 35,000<sup>2</sup>

Ongoing Single Ascending Dose (SAD) study → **1** First formal human safety and efficacy data

Open label Multiple Ascending Dose (MAD) study → **2** Clinical proof of concept

**3** Non-GLP tox. study results inform progression to human trials

**Deep dive on next page**

**4** Human trials commence →

**5** Good Laboratory Practice (GLP) tox. study results

**6** Human trials commence →

Establishing human safety in ADOA enables multiple concurrent Phase 2 studies in different indications (e.g. glaucoma)

1. Based on management forecasts as at 13 March 2024 and subject to successful completion of the Entitlement Offer and all of the risks outlined in Appendix A  
2. Refer to slide 31 for prevalence references

# PYC is set to deliver a major milestone in its polycystic kidney disease program in the immediate future<sup>1</sup>




- PYC anticipates completion of non-GLP Non-Human Primate (NHP) toxicology studies of PYC-003 in Q2 2024
- The results of this study will demonstrate:
  - The safety and tolerability profile of the drug candidate; and
  - Concentration of the drug candidate in the target organ (kidney)
- These results will inform a regulatory submission planned for Q4 2024 to enable human trials to commence
- Polycystic kidney disease is a major cause of morbidity worldwide and represents a >\$10 billion p.a. target market<sup>2</sup> in which the FDA has confirmed an accelerated approval pathway<sup>3</sup>

1. Based on management forecasts as at 13 March 2024 and subject to successful completion of the Entitlement Offer and all of the risks outlined in Appendix A

2. Refer to slide 31 for prevalence references. Market size is projected by multiplying patient prevalence per indication by the median orphan drug price of \$150k p.a. EvaluatePharma. Orphan Drug Report. 2019.

3. Accelerated approval allows for the earlier approval of drugs that treat serious conditions, and fill an unmet medical need based on a surrogate endpoint. FDA has designated Total Kidney Volume as a surrogate endpoint in polycystic kidney disease. <https://www.fda.gov/drugs/development-resources/table-surrogate-endpoints-were-basis-drug-approval-or-licensure>



# PYC Therapeutics

Life-changing science

Overview of the Offer



# Overview of the Offer

Offer	<ul style="list-style-type: none"> <li>• PYC is seeking to raise approximately A\$74.6 million via the issue of approximately 933 million new fully paid ordinary shares (“<b>New Shares</b>”)</li> <li>• The Offer will consist of a 1 for 4 pro-rata accelerated non-renounceable entitlement offer (“<b>ANREO</b>”) (“<b>Entitlement Offer</b>”) (together, the “<b>Equity Raising</b>” or “<b>Offer</b>”).</li> <li>• The Offer comprises an accelerated institutional component open to eligible institutional shareholders and a retail component open to eligible retail shareholders in Australia and New Zealand.</li> </ul>
Offer Price	<ul style="list-style-type: none"> <li>• Offer Price of A\$0.080 per Share, representing a:             <ul style="list-style-type: none"> <li>• 5.9% discount to the last traded price on Wednesday, 13 March 2024</li> <li>• 1.1% discount to the 5-day VWAP of A\$0.081</li> </ul> </li> </ul>
Use of Proceeds	<ul style="list-style-type: none"> <li>• Progress PYC’s first blinding eye disease drug candidate into mid and late-stage human trials</li> <li>• Progress PYC’s second blinding eye disease drug candidate into early and mid-stage human trials</li> <li>• Progress PYC’s polycystic kidney disease drug candidate into human trials</li> <li>• Support progression of the Company’s Phelan-McDermid Syndrome drug discovery and development activities</li> <li>• General working capital and Entitlement Offer costs</li> </ul>
Institutional Entitlement Offer	<ul style="list-style-type: none"> <li>• The Institutional Entitlement Offer will open on Thursday, 14 March 2024 and close Friday, 15 March 2024.</li> </ul>
Retail Entitlement Offer	<ul style="list-style-type: none"> <li>• The Record date for the Retail Entitlement Offer (“Retail Entitlement Offer”) is 4.00pm AWST Monday, 18 March 2024.</li> <li>• The Retail Entitlement Offer will open on Wednesday, 20 March 2024 and close on Monday, 10 April 2024.</li> </ul>
Ranking	<ul style="list-style-type: none"> <li>• New Shares issued under the Entitlement Offer will rank equally with existing Shares from date of issue</li> </ul>
Board Participation	<ul style="list-style-type: none"> <li>• Alan Tribe, Chairman of PYC and substantial shareholder with a beneficial interest of 32.95% of PYC’s total outstanding Shares on issue, intends to subscribe for his full entitlement of A\$24.6 million under the Offer.</li> </ul>
Underwriting	<ul style="list-style-type: none"> <li>• The Offer is not underwritten.</li> </ul>

# Indicative timeline\*



Event	Timing (AWST)
Trading halt	Thursday, 14 March 2024
Announcement of Entitlement Offer	Thursday, 14 March 2024
<b>Institutional Entitlement Offer opens</b>	<b>Thursday, 14 March 2024</b>
<b>Institutional Entitlement Offer closes</b>	<b>4.00pm (AWST) Friday, 15 March 2024</b>
Announcement of results of Institutional Entitlement Offer Trading halt lifted, existing securities commence trading	Monday, 18 March 2024
Record Date for Entitlement Offer	4.00pm (AWST) on Monday, 18 March 2024
Settlement of New Shares under Institutional Entitlement Offer	Tuesday, 19 March 2024
Quotation of New Shares issued under the Institutional Entitlement Offer and commencement of trading of such securities on the ASX	Wednesday, 20 March 2024
<b>Retail Entitlement Offer Opens (Retail Offer Booklet sent)</b>	<b>Wednesday, 20 March 2024</b>
Last day to extend retail offer close date (if required)	<b>Wednesday, 3 April 2024</b>
<b>Retail Entitlement Offer Closes</b>	<b>Monday, 8 April 2024</b>
Announcement of results of Retail Entitlement Offer	Wednesday, 10 April 2024
Allotment and issue of New Shares under Retail Entitlement Offer	Monday, 15 April 2024
New Shares under Retail Entitlement Offer commence trading on ASX	Tuesday, 16 April 2024
Holding statements sent for New Shares issued under the Retail Entitlement Offer	Wednesday, 17 April 2024

\*The timetable above is indicative only and subject to change. The Company reserves the right to alter the dates above in its full discretion and without prior notice, subject to the ASX Listing Rules and the Corporations Act.


# Use of proceeds and Pro Forma Capital Structure - \$75m raise<sup>1</sup>

Sources of funds <sup>2</sup>	Amount
Cash on hand	\$25m
Anticipated FY24 R&D rebate	\$16m
Capital raising proceeds	\$75m

Use of funds <sup>3</sup>	Amount
VP-001 clinical studies	\$21m
PYC-001 completion of IND-enabling studies and commencement of clinical trials	\$22m
PYC-003 completion of pre-clinical and IND-enabling studies and commencement of clinical trials	\$35m
PYC-002 completion of pre-clinical and IND-enabling studies	\$18m
R&D and lab expenses	\$12m
General and Corporate expenses	\$4m
Offer costs and working capital	\$2m

Pro Forma Capital Structure	Amount
Ordinary shares on issue prior to the Offer	3,733m
Undiluted market capitalisation prior to the Offer <sup>4</sup>	\$317.3m
Gross proceeds of the Offer	\$75m
Total New Shares issued under the Offer	933m
Total shares on issue following the Offer	4,666m
Price of New Shares under the Offer	\$0.08
Implied market capitalisation following the Offer	\$392.0m
Options on issue	31.6m

1. Based on management forecasts as at 13 March 2024 and subject to successful completion of the Entitlement Offer and all of the risks outlined in Appendix A
2. Cash on hand as at 1 January 2024; FY24 R&D rebate is based on management's forecast as at 13 March 2024; The Offer is not underwritten and there is no guarantee that the Offer will raise the full \$75m anticipated.
3. The Offer is not underwritten and there is no guarantee that the Offer will raise the full amount contemplated. If the proceeds from the Entitlement Offer are less than what is required to meet the Company's proposed use of funds, the Company may review its proposed use of funds (including whether to scale back or defer investments) as well as consider alternative funding options.
4. Market capitalisation as at 13 March 2024



# PYC Therapeutics

Life-changing science

Corporate Presentation





# PYC Therapeutics

- PYC is a clinical-stage drug discovery and development company with operations in Australia and the US
- The company is an emerging leader in the field of precision RNA therapies for patients with severe diseases caused by insufficient expression of a single gene
- PYC is developing four first-in-class drug candidates in areas of severe unmet need for the tens of millions of patients<sup>1</sup> worldwide affected by these diseases:
  - Retinitis Pigmentosa type 11 (RP11)
  - Autosomal Dominant Optic Atrophy (ADOA)
  - Autosomal Dominant Polycystic Kidney Disease (ADPKD)
  - Phelan-McDermid Syndrome (PMS)
- PYC's novel therapeutics are based on a platform of RNA drugs linked to guiding peptides that overcome the delivery challenge<sup>2</sup> to create a new class of precision medicine

1. Refer to slide 31 for prevalence references

2. Refer ASX announcement for PYC OTS Poster Presentation 3 October 2022



# PYC creates treatment options for the 1 in every 1,000 people\* who have one of these diseases and none available today



• PYC 96.2% ownership of VP-001 (3.8% ownership by Lions Eye Institute, Australia) and 100% ownership of all other pipeline programs  
 • Based on management forecasts as at 13 March 2024 and subject to successful completion of the Entitlement Offer and all of the risks outlined in Appendix A  
 \*Prevalence: disease global prevalence estimates, refer to slide 31 for prevalence references  
 ^ Market size is projected by multiplying patient prevalence per indication by the median orphan drug price of \$150k p.a. EvaluatePharma. Orphan Drug Report. 2019.

# PYC's strategy creates a unique profile for these drug programs

## – differentiated assets with a high probability of success



1. Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank. doi: <https://doi.org/10.1101/2020.11.02.20222232>  
2. <https://endpts.com/roche-launches-institute-of-human-biology-in-search-of-predictive-models/>  
3. Refer ASX announcement 3 October 2022 for PYC OTS Poster Presentation

## Features of PYC's path to market

1. Drugs with the highest probability of success
  - Single gene diseases<sup>1</sup>
  - Effective in models derived from patients<sup>2</sup>
2. In the human data generation window now
  - Clinical proof of concept for multiple assets within 24 months<sup>3</sup>
  - With high success rates in late-stage clinical trials for genetic medicines<sup>4</sup>
3. Anticipating first commercial product launch in 2028<sup>3</sup>
4. Targeting indications in which the FDA is seeking to accelerate approvals<sup>5</sup>

1. Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank. doi: <https://doi.org/10.1101/2020.11.02.20222232>

2. Refer ASX announcements 13 November 2023, 4 October 2023, 7 October 2020 and 16 December 2020

3. Based on management forecasts as at 13 March 2024 and subject to successful completion of the Entitlement Offer and all of the risks outlined in Appendix A

4. Kamb, A., Harper, S. & Stefansson, K. Human genetics as a foundation for innovative drug development. Nat Biotechnol 31, 975–978 (2013). <https://doi.org/10.1038/nbt.2732>

5. <https://lendpts.com/accelerated-approval-will-be-the-norm-for-gene-therapies-fdas-peter-marks-says/>

PYC targets rare diseases caused by a mutation in a single-gene



Drugs targeting single-gene disorders *'are at least five times as likely to be successful'* in human trials<sup>1</sup>


UK Biobank

1. Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank. doi: <https://doi.org/10.1101/2020.11.02.20222232>


# PYC's drug candidates are effective in models derived from patients<sup>1</sup>




**Polycystic kidney**



**Untreated**



**PYC-003 treated**



**Unaffected kidney**




3D model derived from a patient with end-stage renal failure due to polycystic kidney disease

1. Refer ASX announcements 13 November 2023, 4 October 2023, 7 October 2020 and 16 December 2020

# PYC is translating these outcomes into patients now

**PYC's path to market is staged with human data read-outs for first-in-class drugs with disease-modifying potential<sup>1</sup>**



1. Based on management forecasts as at 13 March 2024 and subject to successful completion of the Entitlement Offer and subject to all of the risks outlined in Appendix A

# Genetic medicines have been highly successful in late-stage clinical trials



*“All targets with clear [human] genetic evidence ... produce the clinical effect predicted” (assessment of Phase 3 studies)<sup>1</sup>*

Kamb et al., Nature Biotech

1. Kamb, A., Harper, S. & Stefansson, K. Human genetics as a foundation for innovative drug development. Nat Biotechnol 31, 975–978 (2013). <https://doi.org/10.1038/nbt.2732>


# PYC anticipates its first product launch in 2028<sup>1</sup>

Indication	Market size <sup>2</sup>	Commercialisation <sup>2</sup>		
		2028	2029	2030
Retinitis Pigmentosa 11	\$1 billion p.a.	✓	✓	✓
Polycystic Kidney Disease	\$10 billion p.a.		✓	✓
Optic Atrophy	\$2 billion p.a.		✓	✓

1. Based on management forecasts as at 13 March 2024 and subject to successful completion of the Entitlement Offer and subject to all of the risks outlined in Appendix A

2. Market size is estimated by multiplying patient prevalence per indication by the median orphan drug price of \$150k p.a. (EvaluatePharma. Orphan Drug Report. 2019)

The FDA is seeking to accelerate approval of genetic medicines  
for rare diseases



*“Accelerated approval is going to be the norm for a lot of our initial  
approvals of gene therapies”<sup>1</sup>*

Peter Marks, Director  
FDA Center for Biologics Evaluation and Research

1. <https://endpts.com/accelerated-approval-will-be-the-norm-for-gene-therapies-fdas-peter-marks-says/>


# The ‘Holy Trinity’ in Rare Disease – PYC is developing multiple drug candidates with ‘Holy Trinity’ potential




**Stifel** – the ideal company in rare disease(s) would have three positive traits, and companies with all three of these traits garner outstanding valuations<sup>1</sup>



Median EV (\$m) of Companies by “Holy Trinity” Status and Commercialization Status, May 2020 (N=102)



1. Stifel Biopharma Market Update 26/02/2024 – see slide 81 of [https://www.stifel.com/Newsletters/InvestmentBanking/BAL/Marketing/Healthcare/Biopharma\\_TimOpler/BiopharmaMarketUpdate\\_02.26.2024.pdf](https://www.stifel.com/Newsletters/InvestmentBanking/BAL/Marketing/Healthcare/Biopharma_TimOpler/BiopharmaMarketUpdate_02.26.2024.pdf)  
Data source referenced on slide: CapitalIQ and Stifel Analysis



**PYC**

Therapeutics

Life-changing science

The PYC Team



# PYC's Board and Executive



**Alan Tribe**  
**Chairman**

Experience commercialising Australian technology in US markets, and managing and leading growth companies across technology, resources and retail



**Dr Rohan Hockings**  
**Chief Executive Officer**

Dual-trained in medicine and law with experience across both disciplines in addition to roles in strategy consulting and private equity



**Sri Mudumba**  
**Chief Research & Development Officer**

Over 20 years of experience developing drug delivery products utilising various therapeutic modalities and delivery vehicles from early research through to NDA



**Andrew Taylor**  
**Chief Financial Officer**

Held senior finance positions in ASX listed organisations. Completed multiple capital markets and M&A transactions



**Dr Michael Rosenblatt**  
**Director**

Former Chief Medical Officer of Merck and former CMO of Flagship Pioneering. Deep experience in leading numerous drug development programs, and guiding strategies at biopharma and academic institutions



**Jason Haddock**  
**Director**

Over 20 years' experience in finance, operations and commercialisation of biotechnology companies including at Array BioPharma and Bristol Myers Squibb



**Paula Cunningham**  
**Senior VP Preclinical R&D**

Over 20 years research experience in molecular biology and immunology with expertise in assay development for drug candidate identification

# PYC's Scientific Advisory Board

## **Prof Ian Constable** **Advisory Board**

Renowned Ophthalmologist for over 50 years. Founding Managing Director and now the Patron of the Lions Eye Institute Western Australia. Pioneered first in man gene therapy for macular degeneration

## **Prof Alice Pebay** **Advisory Board**

Stem cell biology expert. Principal investigator of the Neuroregeneration Unit at the Centre for Eye Research Australia, and a Senior Research Fellow in the Department of Ophthalmology at the University of Melbourne

## **A/Prof Fred Chen** **Advisory Board**

Ophthalmologist at Lions Eye Institute (LEI), Royal Perth Hospital and Perth Children's Hospital Western Australia. Performed over 800 vitrectomy surgeries. Lead Research Scientist LEI's Ocular Tissue Engineering Laboratory

## **Dr Josephine Prener-Holtan** **Advisory Board**

Clinician-Researcher and specialist in Retinitis Pigmentosa type 11 - Department of Ophthalmology, pediatric unit, ocular genetic disorders, Oslo University Hospital

## **Dr Naveed Shams** **Advisory Board**


Retinal disease specialist. Past President and CEO of Santen Inc, and Global Head of R&D at Santen Pharmaceuticals, a global ophthalmology company

## **Dr David Birch** **Advisory Board**

Scientific Director, Rose-Silverthorne Retinal Degenerations Laboratory

## **Dr Karl Csaky** **Advisory Board**

Vitreo-retinal disease specialist and current CEO of the Retina Foundation of the Southwest



**PYC**

Therapeutics


Life-changing science

References



# Prevalence references

Program	References for prevalence estimate
Retinitis Pigmentosa type 11	<ul style="list-style-type: none"><li>• Daiger S, et al. 'Genes and Mutations Causing Autosomal Dominant Retinitis Pigmentosa' Cold Spring Harb. Perspect. Med. 2014;5: Ellingford J, et al. 'Molecular findings from 537 individuals with inherited retinal disease' J Med Genet. 2016;53, 761-776</li><li>• Sullivan L, et al. Genomic rearrangements of the PRPF31 gene account for 2.5% of autosomal dominant retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2006;47(10):4579-88</li><li>• Sullivan L, et al. Prevalence of Mutations in eyeGENE Probands with a diagnosis of autosomal dominant retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2013;54(9):6255-61</li><li>• Rose A, and Bhattacharya S. Variant haploinsufficiency and phenotypic non-penetrance in PRPF31-associated retinitis pigmentosa. Clin Genet, 2016;90: 118-126.</li></ul>
Autosomal Dominant Polycystic Kidney Disease	<ul style="list-style-type: none"><li>• Harris PC, Torres VE. Polycystic Kidney Disease, Autosomal Dominant. 2002 Jan 10 [Updated 2022 Sep 29]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews. Seattle (WA): University of Washington, Seattle; 1993-2023.</li><li>• Lakhia R, et al. PKD1 and PKD2 mRNA cis-inhibition drives polycystic kidney disease progression. Nature Communications. 2022;13(1).</li><li>• Cloutier et al. The societal economic burden of autosomal dominant polycystic kidney disease in the United States. BMC Health Serv Res. 2020;20(1):126.</li><li>• Willey et al. Analysis of Nationwide Data to Determine the Incidence and Diagnosed Prevalence of Autosomal Dominant Polycystic Kidney Disease in the USA: 2013-2015. Kidney Dis (Basel). 2019;5(2):107-17.</li></ul>
Autosomal Dominant Optic Atrophy	<ul style="list-style-type: none"><li>• Yu-Wai-Man, P. et al. The Prevalence and Natural History of Dominant Optic Atrophy Due to OPA1 Mutations Ophthalmology. 2010;117(8):1538-46 doi: 10.1016/j.ophtha.2009.12.038</li><li>• Amati-Bonneau, P. et al. OPA1-associated disorders: phenotypes and pathophysiology. The international journal of biochemistry &amp; cell biology, 2009;41(10), 1855-1865. doi: 10.1016/j.biocel.2009.04.012</li></ul>
Phelan-McDermid Syndrome	<ul style="list-style-type: none"><li>• Cochoy DM, et al. Phenotypic and functional analysis of SHANK3 stop mutations identified in individuals with ASD and/or ID. Mol. Autism. 2015;6(23) doi: 10.1186/s13229-015-0020-5 2.</li><li>• Zeidan J, et al. Global prevalence of autism: A systematic review update. Autism Research. 2022;1-13. doi: 10.1002/aur.2696 3.</li><li>• <a href="https://pmsf.org/about-pms/">https://pmsf.org/about-pms/</a></li></ul>



**PYC**  
Therapeutics

*Life-changing science*

**Appendix A: Key Risks**



# Appendix A: Key Risks




## Disclaimer

This section discusses some of the key risks associated with any investment in PYC, which may affect the value of PYC shares. The risks set out below are not listed in order of importance and do not constitute an exhaustive list of all risks involved with an investment in PYC. Before investing in PYC, you should be aware that an investment in PYC has a number of risks, some of which are specific to PYC and some of which relate to listed securities generally, and many of which are beyond the control of PYC. If any of these risks eventuate, they could have a material adverse effect on business, financial condition, PYC share price, operating and financial performance and return to shareholders. Before investing in PYC, you should consider whether this investment is suitable for you. Potential investors should carefully review publicly available information on PYC, carefully consider their personal circumstances (including the ability to lose all or a portion of their investment) and consult their professional advisers before making an investment decision. Many of the risks highlighted in this section may be heightened due to the current economic climate and the current and potential future impact of COVID-19. Additional risks and uncertainties that PYC is unaware of, or that it currently considers to be immaterial, may also become important factors that adversely affect PYC's operating and financial performance.

	<p><b>Technology risk</b></p> <p>For PYC to be competitive in the drug discovery and development market, the Directors expect it will need to continue to develop or acquire new technologies and platforms, develop niche markets and to take early advantage of technological advancements. While the Directors regard PYC's "Peptide Libraries" and "Antisense Oligonucleotide design capabilities" as being at the forefront of drug discovery, competition and new technologies have the potential to negatively impact market share, product prices, profit margins, and the financial value of products. Further, it may render PYC's research projects and the high costs associated with such research and development obsolete. Outcomes of research and development work will affect the future performance of PYC and its Shares.</p>
<p><b>Drug development</b></p>	<p>Drug development is a long and highly regulated process with many identified potential risks. Therapeutics derived from peptides and oligonucleotides are subject to some of these potential risks as described below. These risks can indirectly influence the possibility of PYC to obtain downstream revenue from drug sales or milestone payments and royalties from drugs it discovers or develops being taken through clinical development and subsequent marketing. Difficulty could be encountered with absorption, delivery, metabolism, toxicity, stability, delivery or efficacy in animal or human trials. This could result in early termination of a specific drug candidate program. Formulation difficulties such as poor solubility may also be encountered or other chemical or manufacturing controls related issues which may occur with the drug candidate. Drugs developed from peptides and oligonucleotides may not be suitable for all individuals such as different genetic backgrounds, patients suffering from particular conditions. Unforeseen interactions with other pharmaceuticals or substances may be encountered. Peptides and oligonucleotides that appear specific at early stages of drug discovery may nonetheless exhibit unforeseen side effects in animal or human trials resulting in early termination of the specific drug candidate program. Government regulatory bodies are the final arbiters of approval of drugs for market. Applications for approval may not be granted in all instances in all markets.</p>

# Appendix A: Key Risks contd.



<p><b>Research and development</b></p>	<p>PYC can make no representations that any of its research and development will be successful, that PYC’s development milestones will be achieved or that PYC will develop products that are commercially exploitable. Prior to commercialisation, projects may be delayed or terminated for a range of unexpected scientific, preclinical, clinical, regulatory or commercial reasons. Being at the forefront of both peptide and antisense oligonucleotide drug discovery and development, PYC is entering uncharted territory which may present unforeseen biological complexities. PYC may need to develop new technologies to resolve these complexities and to advance its programs.</p>
<p><b>Operational success is uncertain</b></p>	<p>Clinical trials are complex projects and sometimes fail to provide the anticipated data. For example, the inability to recruit sufficient numbers of patients, or the practical challenges associated with capturing the necessary data, can cause a study to fail, even though the drug itself may be efficacious.</p>
<p><b>Pre-clinical development risk</b></p>	<p>Before PYC’s drug candidates can be considered appropriate for human clinical trialling, candidates must successfully satisfy a number of preclinical requirements. These include the ability to manufacture sufficient amounts of drug of sufficient quality to be used in both preclinical studies and also early stage human clinical trialling. Candidates must demonstrate acceptable safety and tolerability in rigorous toxicology studies. These studies must also reveal a suitable initial dose for use in human trials. There is no guarantee that these requirements will be met, failing which PYC would be unable to develop its products.</p>
<p><b>Clinical development risk</b></p>	<p>The nature of clinical drug development is inherently risky, with many drug candidates failing to be successfully developed into marketable products. Clinical trials have many associated risks which may impact commercial potential and therefore future profitability. Such trials may fail to recruit patients, be terminated for safety reasons, or fail to be completed within acceptable timeframes. Clinical trialling may reveal drug candidates to be unsafe, poorly tolerated or non-effective. Any of these outcomes will likely have a significant adverse effect on PYC, the value of its securities and the future commercial development of its drug candidates including VP-001 (RP11). Clinical trials might also potentially expose PYC to product liability claims in the event its products in development have unexpected effects on clinical subjects.</p>
<p><b>Regulatory approvals necessary for clinical trials</b></p>	<p>PYC may be unable to secure necessary approvals from regulatory agencies and institutional bodies (clinics and hospitals) to conduct its planned clinical trials. There is also no assurance that drug candidates trialled by PYC will prove to be safe and efficacious in clinical trials, or that the regulatory approval to manufacture and market its products will be received.</p>

# Appendix A: Key Risks contd.



<p><b>Competition</b></p>	<p>The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change, both in Australia and internationally, and there are no guarantees about PYC’s ability to successfully compete. Although the Board believes that PYC’s technology is unique and will be effective in identifying and developing drug candidates, there are competing technologies which will continue to be used and other competitors unknown to PYC may emerge from time to time. The introduction of new competitors or a more successful outcome from existing participants may affect the operating performance of PYC.</p>
<p><b>Funding</b></p>	<p>PYC’s long-term value requires its drug candidates to be successful in development and to reach the market. Otherwise, it may be dependent upon the funds raised by this Offer, existing collaboration agreements, and its ability to obtain future equity or debt funding to support commercialisation of development programs. PYC’s ability to raise further equity or debt including ability to divest part of its interest in its drug development programs or assets and the terms of such transactions, will vary according to a number of factors, including the success of research and development results and the future development of PYC’s technology and stock market conditions.</p> <p>While the Directors believe that PYC will have sufficient funds to fund its activities in the short term, PYC is operating in a dynamic and complex industry. There can be no assurance that PYC will not seek to exploit business opportunities of a kind which will require it to raise additional funding from equity or debt sources or divestments including via out-licensing of a drug development program. There can be no assurance that PYC will be able to raise such funding on favourable terms or at all. Any additional equity raising may dilute the interest of Shareholders and any debt financing may involve financial covenants which limit PYC’s operations. If PYC is unable to obtain such additional funding, PYC may be required to reduce the scope of any expansion, which could adversely affect its financial performance.</p>
<p><b>Intellectual Property risks</b></p>	<p>PYC’s success depends in large part on our ability to obtain and maintain patent protection in Australia and other countries with respect to our therapeutic programs and other proprietary technologies we may develop. PYC seeks to protect its proprietary position, in part, by filing patent applications in Australia and abroad relating to our therapeutic programs and other proprietary technologies we may develop. If PYC is unable to obtain or maintain patent protection with respect to our therapeutic programs and other proprietary technologies PYC may develop, its business, financial condition, results of operations and prospects could be materially harmed. Intellectual property rights do not necessarily address all potential threats. The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect PYC’s business or permit PYC to maintain its competitive advantage. For example, others may be able to make products that are similar to any product candidates we may develop but that are not covered by PYC’s intellectual property rights. Similarly, third parties might third parties might conduct research and development activities in jurisdictions where PYC does not have patent or other intellectual property rights and then use the information learned from such activities to develop competitive products for sale in our target commercial markets. Should any of these events occur, they could significantly harm PYC’s business, financial condition, results of operations and prospects.</p>

# Appendix A: Key Risks contd.




<p><b>PYC is dependent on key personnel</b></p>	<p>PYC depends on being able to attract and retain personnel with specialist expertise, and to ensure continuity of key management. The loss of one or more key members of the management team could material affect PYC’s ability to pursue its business plan and to realise value for investors.</p>
<p><b>Research &amp; Development (R&amp;D) Tax Rebate</b></p>	<p>PYC has received R&amp;D rebate(s) on part of its expenditure in research and development. There is a risk that the Australian Government may make material changes to the rebate scheme, which may adversely impact the funding available to PYC to fund its operations. In order to obtain an R&amp;D rebate on that part of its expenditure that is incurred out of Australia PYC must first gain approval for that expenditure from the Australian Government. Such an approval is called an Advanced Finding. PYC prepares Advanced Finding applications from time to time. However, there is no guarantee that this application will be approved</p>
<p><b>Orphan Drug Act</b></p>	<p>The anticipated development timeline and commercial success of PYC’s drug development program is dependent on the assumption that PYC is eligible to receive special designations from the US Food and Drug Administration (FDA) under the Orphan Drug Act 1983. These designations, if received by PYC, would enable, in some cases, priority pathways to commercialisation of a clinical drug program. Additionally, the anticipated pricing of a commercialised product is dependent on PYC meeting the eligibility criteria of that Act. Any changes to the Act or PYC’s eligibility for these designations would have an adverse effect on the commercial success of PYC’s development programs.</p>
<p><b>Partnerships and collaborations</b></p>	<p>PYC relies on partners, collaborators, licensees, and vendors to drive forward its drug development and commercialisation efforts. PYC’s ability to engage such parties in the future is uncertain, and the performance of current parties, while reasonably ensured by customary legal agreements, is also ultimately uncertain.</p>
<p><b>Product liability and uninsured risks</b></p>	<p>Through its intended business, PYC is exposed to potential product liability risks which are inherent in the research and development, manufacturing, marketing and use of its products or products developed with future co-development alliance partners. It will be necessary to secure insurance to help manage such risks. PYC may not be able to maintain insurance for product or service liability on reasonable terms in the future and, in addition, PYC’s insurance may not be sufficient to cover large claims, or the insurer could disclaim coverage on claims. Although PYC endeavours to work to rigorous standards there is still the potential for the products to contain defects which may result in system failures. These defects or problems could result in the loss of or delay in generating revenue, loss of market share, failure to achieve market acceptance, diversion of development resources, injury to PYC’s reputation or increased insurance costs. If PYC fails to meet expectations, PYC’s reputation could suffer and it could be liable for damages. Further PYC is exposed to the risk of catastrophic loss to necessary laboratory equipment, computer equipment or other facilities which would have a serious impact on PYC . PYC gives no assurance that all such risks will be adequately managed through its insurance policies to ensure that catastrophic loss does not have an adverse effect on its performance.</p>

# Appendix A: Key Risks contd.

<b>Regulatory Approval</b>	<p>PYC operates within a highly regulated industry, relating to the manufacture, distribution and supply of pharmaceutical products. Accordingly, PYC is continually exposed to the risk of changes in laws, regulation and government policies in Australia, US, EU and other international target markets. If we fail to comply with the regulatory requirements and receive applicable marketing approvals, our target market will be reduced and our ability to realise the full market potential of our product candidates will be harmed and our business will be adversely affected. We may not obtain regulatory approvals on a timely basis, if at all. Our failure to obtain approval of any of our product candidates by regulatory authorities in another country may significantly diminish the commercial prospects of that product candidate and our business prospects.</p>
<b>Dependence on commercial partners</b>	<p>PYC utilises third parties, including suppliers and third-party service providers for product development, manufacture and commercialisation of products, and certain financial transactional processes. For example, the operation of clinical trials may be outsourced to a contract research organisation. Outsourcing these functions involves the risk that the third party service provider may not comply with regulatory and legal requirements, may not produce reliable results, may not perform in a timely manner or fail to perform at all, may not maintain confidentiality or meet contractual or other obligations. Failure of these third parties could have a material adverse effect on PYC or the success of any of its programs.</p>
<b>Competitive environment may change</b>	<p>Despite customary competitor surveillance, it is possible that development of therapeutic products by other companies will materially, and in an unforeseen way, limit the commercial opportunity associated with PYC's lead drug program, even if it should be successful in clinical trials.</p>
<b>Future access to funding is uncertain</b>	<p>PYC is a pre-revenue company and, as such, is substantially dependent on investors to fund its operations until it is able to generate sufficient cashflows. Future access to equity capital is uncertain. If PYC is unable to fund its continuing operations, the value of PYC may be significantly and adversely affected.</p>
<b>Currency risk</b>	<p>Expenditures in overseas jurisdictions are subject to the risk of fluctuations in foreign exchange markets. For example, PYC has certain payment obligations that are denominated in foreign currencies. Accordingly, payment will be made in those countries' currencies, and may exceed the budgeted expenditure if there are adverse currency fluctuations against the Australian dollar.</p>
<b>Workplace Health and Safety</b>	<p>PYC's business activities may expose its staff to potentially dangerous working environments. Workplace health and safety legislation and regulations differ in each jurisdiction. If any of PYC's employees suffers injury or death, compensation payments or fines may be payable and such circumstances could result in the loss of a licence or permit required to carry on the business. Such an incident may also have an adverse effect on the PYC's business and reputation.</p>
<b>Litigation</b>	<p>There has been substantial litigation and other proceedings in the pharmaceutical and biotechnology industries. There is a risk that PYC may in future be the subject of or required to commence litigation. There is, however, no litigation currently underway or threatened.</p>
<b>Dividends</b>	<p>PYC has never paid a dividend and PYC does not intend on paying dividends in the foreseeable future which means that holders of shares may not receive any return on their investment from dividends.</p>

# Appendix A: Key Risks contd.




<p><b>Cyber security</b></p>	<p>PYC relies heavily on its information technology systems including its networks, equipment, hardware, software, telecommunications and other information technology (collectively, IT Systems), and the IT Systems of third-party service providers, to operate its business as a whole. PYC's operations depend on the timely maintenance, upgrade and replacement of its IT Systems, as well as pre-emptive efforts to mitigate cybersecurity risks and other IT System disruptions.</p> <p>IT Systems are subject to an increasing threat of continually evolving cybersecurity risks from sources such as computer viruses, cyber-attacks, natural disasters, power loss, defects in design, security breaches and other manipulation or improper use of the Company's systems and networks, resulting in, among other things, unauthorised access, disruption, damage or failure of the Company's IT Systems (collectively, IT Disruptions). Although to date the Company has not experienced any material data losses or financial impost relating to such IT Disruptions, there can be no assurance that it will not incur such losses in the future.</p> <p>The occurrence of one or more IT Disruptions could have effects such as damage to the Company's equipment, downtimes, operational delays, destruction or corruption of data, increases in capital expenditures, expensive remediation efforts, distraction of management, damage to the Company's reputation or events of noncompliance which could lead to regulatory fines or penalties or ransom payments. Any of the foregoing could have a material adverse effect on PYC's results of operations and financial performance.</p>
<p><b>Economic risk and market forces</b></p>	<p>Any deterioration in the domestic and global economy may have a material adverse effect on the performance of PYC business and PYC's share price. It is possible that new risks might emerge as a result of Australian or global markets experiencing extreme stress, or existing risks, and may manifest themselves in ways that are not currently foreseeable. The equity markets have in the past and may in the future be subject to significant volatility. Other factors including, but not limited to, political movements, stock market trends, changing customer preferences, interest rates, inflation levels, commodity prices, industrial disruption, environmental impacts, international competition, taxation changes and legislative or regulatory changes, may all have an adverse impact on PYC's operating costs, profit margins and share price. These factors are beyond the control of the Company and PYC cannot, to any degree of certainty, predict how they will impact the Company.</p>
<p><b>Share Investment</b></p>	<p>There are risks associated with any investment in equity capital and stock markets. The market price of PYC shares will fluctuate due to various factors, many of which are out of PYC's control, such as general movements in the stock markets, recommendations by brokers and analysts, changes in inflation rates and interest rates, changes in government, fiscal, monetary and regulatory policies, global geopolitical events and hostilities, acts of terrorism and investor perceptions. As a consequence, PYC shares may trade at a higher or lower price than the issue price of the Offer shares. Equity capital markets are subject to significant volatility and PYC, its directors and its management cannot guarantee the performance of the shares issued under the Offer.</p>

# Appendix A: Key Risks contd.



<p><b>Dilution risk</b></p>	<p>Existing shareholders who do not participate in the Offer will be diluted as a result of the issue of new shares. A participating shareholder may still be diluted even though they participate in the Offer, depending on the number of shares issued to them. In the future, PYC may decide to issue additional shares to raise funds for operations or acquisitions the company decides to make, and shareholders may be diluted as a result.</p>
<p><b>Liquidity risk</b></p>	<p>There is no guarantee of an active market for PYC shares or that the price of PYC shares will increase. Shareholders who wish to sell their Offer shares may be unable to do so at an acceptable price, or at all, if insufficient liquidity exists in the market. Therefore, changes in the prevailing market price of PYC shares may result in a loss of money invested for shareholders.</p>
<p><b>Taxation</b></p>	<p>Changes to taxation laws and in the way taxation laws are interpreted may impact the tax liabilities of PYC, shareholder returns, the level of dividend imputation or franking, or tax treatment of a shareholder's investment. In particular, both the level and basis of taxation may change. Frequent changes to taxation laws may cause compliance issues and any failure by PYC to comply with evolving laws may increase its tax liabilities or expose the company to enforcement action. An investment in shares involves tax considerations that differ for each investor. Investors should consult with a tax professional in connection with any investment in PYC.</p>
<p><b>COVID-19 and global health risks</b></p>	<p>Global health risks or the potential for these events could have a negative impact on PYC. Since early 2020 the coronavirus pandemic, now known as COVID-19, has spread rapidly to many countries globally. The impact of COVID-19 has led to the adoption of extreme preventative measures by governments and other authorities, including the imposition of limits on public gatherings, restrictions on travel, the closure of borders, requirements for self-isolation, restriction of access to services and the closure of stores and businesses, including in Australia. Given the high degree of uncertainty surrounding the extent and duration of COVID-19 it is not possible to assess the impact of COVID-19 on PYC's business. These events have had and can be expected to continue to precipitate sudden significant changes and volatility in regional and global economic conditions and financial markets. If there is a significant increase in the number of COVID-19 cases, this may burden hospitals and healthcare institutions to the extent that all non-urgent medical procedures, including clinical trials, may be cancelled or postponed indefinitely. This may impact the ability of PYC to progress the phases of their clinical trials. As a result, the operations of PYC may be significantly adversely affected by such events.</p>



**PYC**  
Therapeutics

*Life-changing science*

Appendix B: International Offer Restrictions



# Appendix B: International Offer Restrictions



## NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES

### International Offer Restrictions

This document does not constitute an offer of new ordinary shares (New Shares) of the Company in any jurisdiction in which it would be unlawful. In particular, this document may not be distributed to any person, and the New Shares may not be offered or sold, in any country outside Australia except to the extent permitted below.

#### New Zealand

This document has not been registered, filed with or approved by any New Zealand regulatory authority under the Financial Markets Conduct Act 2013 (the “FMC Act”).

The New Shares are not being offered to the public within New Zealand other than to existing shareholders of the Company with registered addresses in New Zealand to whom the offer of these securities is being made in reliance on the Financial Markets Conduct (Incidental Offers) Exemption Notice 2021.

Other than in the entitlement offer, the New Shares may only be offered or sold in New Zealand (or allotted with a view to being offered for sale in New Zealand) to a person who:

- is an investment business within the meaning of clause 37 of Schedule 1 of the FMC Act;
- meets the investment activity criteria specified in clause 38 of Schedule 1 of the FMC Act;
- is large within the meaning of clause 39 of Schedule 1 of the FMC Act;
- is a government agency within the meaning of clause 40 of Schedule 1 of the FMC Act; or
- is an eligible investor within the meaning of clause 41 of Schedule 1 of the FMC Act.

#### Switzerland

The New Shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange or on any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering or marketing material relating to the New Shares constitutes a prospectus or a similar notice, as such terms are understood under art. 35 of the Swiss Financial Services Act or the listing rules of any stock exchange or regulated trading facility in Switzerland.

No offering or marketing material relating to the New Shares has been, nor will be, filed with or approved by any Swiss regulatory authority or authorised review body. In particular, this document will not be filed with, and the offer of New Shares will not be supervised by, the Swiss Financial Market Supervisory Authority (FINMA). Neither this document nor any other offering or marketing material relating to the New Shares may be publicly distributed or otherwise made publicly available in Switzerland. The New Shares will only be offered to investors who qualify as “professional clients” (as defined in the Swiss Financial Services Act). This document is personal to the recipient and not for general circulation in Switzerland.

## COMPLETION OF INSTITUTIONAL ENTITLEMENT OFFER

- **PYC has raised \$40 million<sup>1</sup> through the institutional component of the Accelerated Non-Renounceable Entitlement Offer (ANREO) announced to the market on 14 March 2024**
- **Subscriptions have been received for all New Shares that were available under the accelerated component of the ANREO<sup>2</sup>**
- **PYC is now funded through multiple important upcoming milestones across its drug development pipeline including human safety and efficacy read-outs**
- **Retail shareholders have an opportunity to subscribe for New Shares in the Company through the Retail Entitlement Offer on the same terms as those offered in the Institutional Entitlement Offer**

### PERTH, Australia and SAN FRANCISCO, California – 18 March 2024

PYC Therapeutics Limited (ASX:PYC) (**PYC** or the **Company**) today announces the successful closure of the institutional component of the Entitlement Offer to raise up to approximately \$74.6 million announced to the ASX on 14 March 2024.

The Institutional Entitlement Offer was fully subscribed, having received firm commitments for a total of \$40 million. The Retail Entitlement Offer could raise up to a further \$34.6 million for a total of up to ~\$74.6 million under the Entitlement Offer.

CEO, Dr Rohan Hockings commented on the Equity Raising:

*"These funds will enable PYC to generate critical human data in support of our pipeline of first-in-class drug candidates. Human data is the currency of our industry and we are grateful for the support of our shareholders as we move into this exciting window for the Company"*

New Shares subscribed for under the Institutional Entitlement Offer are expected to settle on Monday 25 March 2024.

PYC expects its shares to recommence trading on the ASX on an ex-entitlement basis with effect from the open of market today, Monday 18 March 2024.

---

<sup>1</sup> Before costs

<sup>2</sup> Defined terms have the meaning given to them in the announcement of the offer (see ASX announcement of 14 March 2024)

## Retail Entitlement Offer

The Retail Entitlement Offer will be conducted on the same terms as the Institutional Entitlement Offer.

The Retail Entitlement Offer will be open to eligible retail shareholders with registered addresses in Australia and New Zealand, as at the record date. The Retail Entitlement Offer will open on Wednesday 20 March 2024 and is expected to close at 5.00pm AWST on Monday 8 April 2024.

New Shares issued under the Retail Entitlement Offer are expected to be issued on Monday 15 April 2024. PYC will seek quotation of the New Shares issued under the Retail Entitlement Offer on the ASX.

The directors have reserved the right to place any shortfall within 3 months of the close of the Entitlement Offer at the Board's discretion but at a price no less than the Offer Price.

This announcement was approved for release by the Board of PYC Therapeutics Limited.

## About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. PYC's drug development programs target monogenic diseases – **the indications with the highest likelihood of success in clinical development**<sup>3</sup>.

The Company was the first to progress a drug candidate for a blinding eye disease of childhood into human trials. The Company is progressing a second blinding eye disease (Autosomal Dominant Optic Atrophy) and a third program targeting Polycystic Kidney Disease which are anticipated to commence human trials in mid-2024 and late 2024 respectively.

For more information, visit [pyctx.com](http://pyctx.com), or follow us on LinkedIn and Twitter.

## Forward looking statements

*Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations, and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations, and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.*

---

<sup>3</sup> Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank  
<https://doi.org/10.1101/2020.11.02.20222232>

*This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.*

*This ASX announcement was approved and authorised for release by the Board of PYC Therapeutics Limited*

## **CONTACTS:**

**INVESTORS and MEDIA**

info@pyctx.com